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Asthma is a complex respiratory disease that has been increasing in prevalence in the United 
States since 1980 despite advances in treatment. Approximately 32.6 million Americans have 
had asthma at one point in their lives; while 22.2 million Americans are currently diagnosed with 
asthma. Severe asthma occurs in approximately 10% of those asthmatics. A distinct racial 
disparity exists within the severe asthma population, with Blacks having a greater likelihood of 
having poorly controlled disease compared to their White counterparts. The factors that 
contribute to this disparity are not truly known; however, it has been suggested that genetics, the 
environment, and socioeconomics play a role in the disparity. 
This dissertation focused on the role that biologic, genetic, and socioeconomic factors 
play in the development of severe asthma using data from the Severe Asthma Research Program 
(SARP). The overall hypothesis was that Blacks are predisposed to an allergic, early onset 
asthma phenotype, which fundamentally differs from the asthma observed in Whites on the basis 
of biologic/genetic differences in  disease process. The overall aim of this study is to assess the 
extent to which the racial disparity in asthma is attributable to the differences in the pathobiology 
of asthma. The first paper sought to assess the extent to which racial disparities between Black 
and White adult asthmatics with severe asthma are attributable to physiologic, 
immunoinflammatory, and sociodemographic variables. The second paper, utilizing the results 
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from paper 1, examined the  factors that drive the increased production of immunoglobulin E 
(IgE) in Blacks, as well as the primary factors that contribute to severe asthma in Blacks with 
high IgE. The third paper presents some of the policy issues that affect the racial disparity seen in 
severe asthma and five recommendations that will aid in the reduction of the widening gap 
between Black and White asthmatics. IgE, along with family history of asthma, were shown to 
be a strong predictors of severe asthma in Blacks, while comorbidities were  predictors for 
Whites. The public health significance of this study is that different interventions can now be 
created to effectively treat asthma in Blacks versus Whites.  
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1.0  DISSERTATION OVERVIEW AND OBJECTIVES 
Asthma is a complex respiratory disease that has been increasing in prevalence in the United 
States since 1980 despite advances in treatment. It is estimated that 32.6 million people (1 in 10 
Americans) in the United States has had asthma at one point in their lives; while 22.2 million 
people (1 in 14 Americans) are currently diagnosed with asthma[1]. Among the over 20 million 
people with asthma, over 12 million have had an asthma attack within the past 12 months. 
Asthma is associated with high morbidity and mortality. In the United States, about 30,000 
people a day have an asthma attack, while 5,000 people have an emergency department visit and 
1,000 people are admitted to the hospital due to their asthma. Almost 11 Americans die each day 
due to their asthma, while 4,000 die annually from complications related to asthma.  Due to these 
statistics, asthma has become an increasing burden on the individual diagnosed with asthma and 
the American health care system, costing $19.7 billion annually[1]. 
Asthma has become a topic of interest and research due to the complexity of the disease 
and the need to understand the impact that the disease has on patients. Currently, there is no 
standard or universal definition for asthma that is pathophysiologically and clinically 
applicable[2]. Asthma is typically identified in a person complaining of difficulty in breathing, 
paroxysmal cough and wheezing, and chest tightness which is due to the intermittent narrowing 
or blockage of the airways. There is no cure for asthma but some individuals do not experience 
any symptoms until there is an asthma episode. These episodes are often characterized by the 
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swelling of the lining of the airways with the muscles tightening around these airways[1]. Over a 
period time, repeated episodes may lead to chronic, irreversible airway changes. In more severe 
asthma attacks, the cells of the ciliated lining become so damaged that they contribute to the 
obstruction of the airways through the production of mucus[1]. In 1962, the American Thoracic 
Society (ATS) first defined asthma as “a disease characterized by increased responsiveness of 
the trachea and bronchi to various stimuli and manifested by the narrowing of the airways that 
changes in severity either spontaneously or as a result of therapy” [2]. Due to recent research 
proving that asthma also involves inflammation and hyper-responsiveness of the airways to the 
lungs, the definition of asthma has evolved. The National Institutes of Health and National Heart 
Lung and Blood Institute defined asthma as a disease which increased airway hyper-
responsiveness and inflammation that often leads to coughing, wheezing, shortness of breath, 
and tightness in the chest with obstruction to the airways[2]. Along with there being no cure for 
asthma, there is also no concrete evidence to what causes asthma. Past research has suggested 
many risk factors or triggers for the development of asthma such as indoor and outdoor allergens 
(i.e., tobacco smoke or pollen), family history of asthma, obesity, and viral infections[1].  
More women than men are affected by asthma, and minorities, mainly Blacks, have a 
higher prevalence of asthma compared to Whites. Blacks are disproportionately affected by 
asthma and have the higher asthma morbidity and mortality rates. The prevalence of asthma for 
Black children in 2004 was reported to be 12.5% compared to 7.5% in White children[2]. 
Children are twice as likely and are more vulnerable to developing asthma than adults. There are 
over 5 million children in the United States affected by asthma which results in an increase in the 
number of days of school missed (absenteeism)[1]. It has been shown in past studies that 
socioeconomic status is associated with the risk of developing asthma. People living in poor or 
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urban neighborhoods tend to be exposed to the allergens that affect asthma sufferers such as 
cockroach dust, mold, and dust mites[1]. Black children from poor urban neighborhoods have 
some of the highest risk for developing asthma[2]. 
As the prevalence of asthma increases, the costs associated with asthma increase.  
Annually, direct costs of health care for asthma are $10 billion, while indirect costs are $8 
billion[1]. Direct costs include hospitalizations, emergency room visits, and doctor’s office 
visits. Indirect costs include lost wages and transportation costs.  
This dissertation aims to identify factors associated with asthma severity in two different 
racial groups, Blacks and Whites. A cross-sectional analysis in a sample of Blacks and Whites 
will examine risk factors for severe asthma in each group to see if they differ. Another study will 
examine the predictors of high IgE and asthma severity in Blacks. The last study focuses on the 
policy issues that affect the racial disparity seen in severe asthma and recommendations on 
overcoming those issues. The overall aim of this study is to assess the extent to which the racial 
disparity in asthma is attributable to differences in the pathophysiology of asthma. We, therefore, 
hypothesize that African Americans are predisposed to an allergic, early onset asthma 
phenotype, which fundamentally differs from the asthma observed in Caucasians on the basis 
of biologic/genetic differences in the disease process.    
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2.0  INTRODUCTION 
2.1 EPIDEMIOLOGY OF SEVERE ASTHMA 
2.1.1 Severe Asthma Phenotype 
Although there are treatments that can control asthma, there are still a small number of 
asthmatics (about 10%) that are not able to control their asthma despite the use of the highest 
treatment level (i.e., high dose of inhaled corticosteroids (ICS)) [3-5]. They define the severe 
asthma phenotype. There are several names for this type of asthma: chronic severe asthma 
(CSA), severe asthma, and refractory asthma. Individuals with severe asthma are characterized 
by their inability to have their asthma controlled with current available medications; however, 
severe asthma should not be mistaken as “poorly controlled” asthma. They have persistent daily 
symptoms, daily bronchodilator use, asthma-related nocturnal symptoms at least once a week, 
and a force expiratory volume in 1 second of less than 75% predicted for their age, height, sex, 
and race[4]. Asthma phenotypes help distinguish subgroups of asthma. Phenotype is defined as 
“the visible characteristics of an organism resulting from the interaction between its genetic 
makeup and the environment”[6]. Dr. Sally Wenzel states that there are three categories for 
asthma phenotypes: clinical or physiological phenotypes; phenotypes related to triggers such as 
aspirin, environmental allergens, menses, exercise, and occupational allergens; and inflammatory 
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phenotypes[6]. The severity-defined phenotype is classified under the clinical phenotypes. 
Having lower lung function, a history of pneumonia, less atopy, and being Black has been shown 
to be associated with having more severe and frequent exacerbations, hence suggesting their 
contribution to the development of severe asthma[6, 7]. Asthma severity can be measured 
according to the potential for frequent exacerbations and the degree of airway obstruction 
(disease severity) measured as baseline forced expiratory volume in one second (FEV1)[8]. 
Currently, there is no way to determine if a patient with asthma is at risk of developing severe 
asthma. A reduction in FEV1 does not necessarily explain everything about disease progression; 
therefore, additional risk factors may contribute to the risk of developing severe asthma[9]. 
In 2004, a study at National Jewish Medical Center with 80 individuals with severe 
asthma detailed the differences between early and late onset severe asthma. There were several 
differences between the two groups. In the early onset group, there was more of a genetic 
influence and response to allergens. On the contrary, in the late onset group, it tended to vary 
among individuals with results showing both allergic and non-allergic responses. Almost all of 
the individuals with early onset severe asthma (98%) had positive skin allergen tests, whereas, 
only 76% of the late onset group had positive skin tests. Pulmonary function (FEV1 and FVC) 
was noticeably worse for those with late onset severe asthma compared to the early onset group. 
Late onset severe asthmatics were also shown to have higher numbers of eosinophils, whereas, 
the early onset severe asthmatics had higher numbers of tissue lymphocytes[9]. Table 1 below 
displays the differences between the early onset and late onset severe asthma groups. 
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Table 1 Distinguishing Features of Early- and Late-Onset Asthma[9] 
 Early Late 
Atopy Very High Moderate 
Allergic Symptoms 
Evidence for Th2 immunity 
Very High 
High 
Moderate 
Moderate 
Family History High Low 
History of atopic dermatitis High Low 
Persistent eosinophilia Moderate High 
Urinary cysteinyl leukotrienes 
History of initiating infection 
Moderate 
Moderate 
High 
High  
 
2.1.2 Prevalence of asthma and severe asthma 
Asthma has been increasing in prevalence and severity despite the availability of effective 
medications and treatments. The National Center for Health Statistics has frequently reported on 
the prevalence of asthma since 1980 through the use of the National Health Interview Survey 
(NHIS). From 1980-1996 the prevalence of asthma in the United States was reported through the 
use of questionnaires. Having at least one asthma attack episode within the past 12 months was 
considered to be a self-report of asthma. In 1980, 31.4 per 1000 population (69 million people) 
reported having asthma, whereas, in 1996, 54.6 per 1000 population (14.6 million people) 
reported having asthma. From 1980-1996, the prevalence of asthma rose by 74% according to 
Reprinted with permission of the Severe Asthma Research Program. Copyright © Severe Asthma Research Program. 
Sally Wenzel/2011/Severe Asthma in Adults/Distinguishing Features of Early- and Late-Onset Asthma figure is taken 
from pg 153. American Journal of Respiratory and Critical Care Medicine. 
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NHIS reports. However, in 1997 the NHIS was revised to accurately determine whether 
individuals truly had asthma. The questionnaire was revised to include a question that asked 
“Have you ever been told by a health care professional that you have asthma?” and the individual 
was followed for one year to capture any episodes of asthma. With the revisions, the prevalence 
of asthma decreased slightly from the previous year to 40.7 per 1000 population (11.1 
million)[2]. Having a stricter definition of asthma ensured that individuals with asthma were 
being captured and not just individuals who may have had asthma symptoms such as wheezing 
but do not have clinical asthma as defined by medical professionals.  
There are several reasons that may explain the increase in the prevalence of asthma in the 
United States over the past two decades. Americans are living more sedentary lifestyles, thus, the 
rates of obesity and other diseases have been steadily increasing. Obesity has been linked to 
asthma as a possible risk factor for its development. Along with the sedentary lifestyle comes 
more time spent indoors by children and adults, which has become increasingly popular 
behavior. Exposure to allergens has been shown to be related to atopy, which is linked to the 
development of asthma. Spending more time indoors increases an individual’s chances of being 
exposed to indoor allergens such as dust mites, cockroach dust, and mold, which have all been 
linked to the development of asthma. Also, over the years industrialization has become more 
prevalent, thus, increasing the amount of pollution in the environment or environmental triggers. 
Airway hyperresponsiveness is a result of this exposure to environmental triggers, thus 
increasing the risk of developing asthma[2].  
The prevalence of asthma is different among the races and age groups. The prevalence of 
asthma is higher among children aged 5-14; however, Black children have a higher prevalence of 
asthma compared to their White counterparts, 12.5% and 7.5%  respectively, as shown in 2004. 
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This could be partially due to the increased exposure to allergens at an earlier age due to urban 
and poorer living environments. In 2004, Black adults were, also, shown to have a higher 
prevalence of asthma compared to White adults, 8.1% and 7.4%, respectively[2]. It is not known 
whether this number includes individuals who were diagnosed with asthma as a child and their 
asthma persisted into adulthood because age of onset was not collected. It can be hypothesized 
that the disparity between Blacks and Whites would be more pronounced with a larger gap 
between the two numbers; Blacks having many more diagnoses of asthma compared to Whites.   
In contrast to general asthma, approximately 10% of the asthma population suffers from 
severe asthma, as previously described. Little is known about why and how severe asthma 
develops. Genetics, environmental factors, the combination of the genetics and the environment, 
or the occurrence of an acute event at the onset of asthma that results in a structural change in the 
lungs have not been ruled out as possible causes for the development of severe asthma[9].  
2.1.3 Morbidity and mortality of asthma and severe asthma 
Increasing morbidity is associated with more severe asthma. Individuals with severe asthma tend 
to visit the emergency room more frequently, have more hospitalizations, lower quality of life 
and high functional impairments or limitations[10]. Health care utilization is high for individuals 
with asthma and higher for those with severe asthma. A marker for severe asthma is typically the 
use of the emergency room. 
Racial differences in asthma morbidity and mortality have frequently been studied. 
Morbidity and mortality in asthma are disproportionately higher in Blacks compared to Whites, 
despite the fact that asthma prevalence and asthma-related deaths have been decreasing 
overall[11]. Blacks have been shown to not only have higher prevalence rates for asthma, but 
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they are four times more likely to be hospitalized due to asthma and five times more likely to die 
as a result of asthma[12]. Gupta et al examined the morbidity and mortality rates in the United 
States from 1980-2002 by age and race. Annually, an average of 438,700 hospitalizations and 20 
hospital discharges per 10,000 were due to asthma between the years of 1980 and 2002. Whites 
decreased from 9.0 to 6.1 discharges per 10,000 population between 1980 and 2002. Blacks 
hospitalization rates slightly decreased from 25.2 to 24.6 discharges per 10,000 population. 
Blacks had much higher rates of asthma hospitalizations compared to Whites during the same 
time period. The rate difference between Blacks and Whites increased from 1980 to 2002, 16.3 
to 18.5 discharges per 10,000 population. Much of the increase seen in the racial rate differences 
was seen in children (aged 5-18 years old). White children hospitalization rates decreased from 
11.5 to 8.1 discharges per 10,000 population; whereas, the hospitalization rates for Black 
children increased from 34.3 to 36.5 discharges per 10,000 population between 1980 to 
2002[12]. 
Ginde et al used emergency room visits as the benchmark for asthma morbidity in a 
population and used the National Hospital and Ambulatory Medical Care Survey to describe 
trends in asthma morbidity for Blacks and Whites[13]. In 1998, the rate of asthma-related 
emergency room visits peaked at 7.6 per 1000 persons but decreased to 6.0 per 1000 persons by 
2005 indicating some progress has been made to decrease asthma morbidity with respect to 
emergency room visits. However, when looking at the race-specific rates of emergency room 
visits, it appears that progress is not seen in both races. Whites decreased their rate of asthma-
related emergency room visits by 25% from 1998 to 2005; whereas, the rates for Blacks steadily 
increased since 2000. The rate difference between Blacks and Whites increased from 2.5 per 
1000 persons to 4.5 per 1000 persons[13]. The CDC’s National Surveillance for Asthma from 
  10 
1980 to 2004 showed similar racial disparities in emergency room visits for children and adults 
together. Black children and adults had higher asthma-related emergency room visits compared 
to White children and adults, 21.0 per 100 and 7.0 per 100, respectively.  
Death as a result of asthma is rare; however, it can occur[2]. The mortality rate for 
asthma was 1.31 deaths per 1,000,000 population (218 deaths) in 5 to 34 year olds between 1980 
and 2001 in the United States. In Whites, the mortality rate increased from 2.1 to 2.6 deaths per 
1,000,000 population from 1980 to 2001. In contrast, the mortality rate for Blacks increased from 
9.9 to 13.2 per 1,000,000 population during the same time period. The rate difference between 
Blacks and Whites during this time period increased from 7.8 to 10.6 deaths per 1,000,000 
population. Interestingly, the rate difference for Black and White young adults (aged 19-34 year 
old) was 14.7 deaths per 1,000,000 population[12]. 
Some studies speculate that the cause of the racial gap in mortality rates is related to the 
lack of access to care, high prevalence rates, and more severe asthma among Blacks. In a study 
by Zoratti et al, Blacks were shown to have more visits to the emergency room, more 
hospitalizations, fewer visits to an asthma specialist, fewer inhaled corticosteroid use, and more 
oral corticosteroids prescribed[2]. Incorrect diagnosis of a severe asthma attack or physicians 
underestimating the severity of asthma symptoms along with no early intervention my also be 
contributing to the increased mortality rate among Blacks compared to Whites[2, 15].  
2.1.4 Economic burden of asthma and severe asthma 
Due to asthma being a chronic condition, use of daily medication is needed to control the 
disease; however, despite effective prophylactic therapy available to asthmatics, the prevalence 
and severity are steadily increasing. Asthmatics not properly managing their asthma by under-
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using medications have resulted in the health systems incurring substantial costs[16]. In addition, 
severe asthma continues to excessively contribute to the economic burden and costs of asthma 
due to the difficult nature of the disease[9]. In 2005, 1% of the total health care cost for the 
United States was attributed to asthma costs. Treating uncontrolled and severe asthma accounted 
for the majority of these costs[16].  
Individuals with asthma tend to acquire a considerable financial burden because of their 
asthma[2]. Direct, indirect, and intangible costs to asthma care can negatively affect the 
individual with asthma and their family. Direct costs consist of costs associated with physician 
costs, hospital costs, and drug costs. Physician costs account for the smallest amount of asthma 
costs. Typically, 20-25% of the direct costs for asthma is for hospital care such as in-patient care 
or emergency room care. Patients with more severe asthma tend to incur these hospital costs. 
Drug costs are the most expensive component of direct costs for asthma making up 37% of the 
total asthma direct cost. Poor compliance with asthma medication results in an increase in 
asthma morbidity, thus, resulting in an increase in the costs associated with asthma[16]. 
Indirect costs consist of resources that are lost due to the disease such as premature 
retirement, time off of work, absenteeism, or death. These costs occur only when asthma has 
become intrusive into the lifestyle of the individual. These costs vary depending on the severity 
of the asthma and age of the individual[16]. Hospitalizations and urgent care have resulted in 
almost $20 billion in annual asthma health care costs, direct and indirect included[1]. 
Absenteeism is a common problem associated with asthma morbidity. Every year, over three 
million days of work and ten million days of school are lost due to asthma[17]. In a study with 
over 2500 caregivers for children with asthma and adults with asthma, approximately 50% of 
children with asthma and 25% of adults with asthma reported missing school or work due to their 
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asthma. Being hospitalized, visiting the emergency room, or visiting an urgent care facility for 
their asthma was the reason why 41% of adults and 54% of children missed school or work[2].  
Intangible costs occur when the quality of the individual’s life is impaired. These costs 
also vary depending on the age of the individual and severity of the asthma[16]. Individuals with 
asthma may become depressed or feel as though their lives are very restricted or limited due to 
their asthma, thereby, resulting in a decrease in their quality of life.  
The more severe the asthma, the higher the costs associated with asthma care18]. 
2.1.5 Management of asthma and severe asthma 
A small fraction of asthma cases exhibit severe exacerbations and severe episodes of asthma. It is 
imperative that individuals with severe asthma receive optimal care that avails additional 
attention and care to their condition. Management of asthma can reduce the morbidity that is 
associated with severe asthma and increase quality of life[17]. According to the Global Initiative 
for Asthma (GINA) global guidelines, achieving and maintaining control of asthma symptoms in 
the long-term is the primary goal of asthma treatment[19, 20]. An assessment of each individual 
with asthma should occur to initially to determine the individual’s current treatment plan, level 
of control, and compliance and adherence to the treatment regimen[19].  One study concluded 
that although management can improve asthma care, full asthma control is not always the result 
in all individuals[21].   
Blacks have a higher prevalence of asthma than Whites and this disparity is also evident 
with respect to the management of asthma. This may be the reason why more Blacks have 
emergency room visits compared to Whites[22]. Black children have been shown to have a 
higher prevalence of uncontrolled asthma compared to White children. Besides the possibility 
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that they may have more exposure to indoor allergens and poverty, lack of access to quality care 
and the inability to afford medication is a cause for the disparity seen in childhood asthma[2].  
White children were more likely to have a codiagnosis of asthma and allergies (68%)[23]. 
Also, children with public insurance and children who use the emergency department as their 
primary source of care had the lowest prevalence of diagnosed allergies[23]. Children that 
reported being tested for allergies were less likely to report exposure to household allergens, 
more likely to receive allergy education and treatment, and less likely to report an episode of 
wheezing in the past two weeks compared to children who did not receive allergy testing[24].  
Blacks tend to rate their doctor-patient communication as poor[24], thus, suggesting the 
need for better communication between physicians and Black patients. Studies have, as well, 
shown that physicians may not effectively manage the asthma of a Black patient nor 
communicate effectively with Blacks. This could be the result of the presence of ecological 
fallacies[25] or a provider bias due to stereotypes or clinical uncertainty [24]. It is important for 
clinicians not to stereotype each Black patient based on results from past studies or personal 
feelings about race. Disparities in education and income paired with the past legacy of racial 
discrimination can contribute to the disparity in health care. “The manner in which societal and 
historical factors influence the experience of the health care process are complex and not readily 
summarized numerically[26].” Managing asthma is a complex and challenging issue; however, 
there are ways to effectively do it. Asthma can be successfully managed with patient 
education[26], patient adherence to medications, good physician-patient communication[24], 
early diagnosis, and understanding patient’s belief[27, 14, 28]. Management of asthma can, in 
essence, improve an individual’s quality of life.  
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2.2 PATHOPHYSIOLOGY OF SEVERE ASTHMA 
It is important to look at the pathophysiology of asthma and immuno-inflammatory 
characteristics of asthma. FEV1 is a sensitive measure of airflow obstruction (and is associated 
with risk of exacerbations) and can be used to monitor lung function changes over time. To 
identify airway hyper-responsiveness a metacholine inhalation challenge test is used to 
determine the sensitivity of the smooth muscle to spasm[29].  It is also very important to 
consider exposure and sensitivity to allergens such as cat dander, dust mites,  and ragweed as 
possible risk factors[29]. Among the phenotypes that Dr. Wenzel mentioned, the exacerbation-
prone phenotype and eosinophilic phenotype are important to study when discussing asthma 
pathophysiology.  Exacerbation-prone asthmatics are characterized by their frequency to have 
moderate to severe exacerbations which can be described as severe asthma if the frequency and 
severity of the exacerbations is high[6]. Some of the risk factors for severe exacerbations are: 
Black race, low FEV1, early age of onset, low provocation concentration 20 (PC20) and 
bronchodilation responsiveness, and a high percentage of sputum eosinophils[6]. The more 
common and prominent exacerbating phenotype is the eosinophilic inflammatory phenotype. 
Results have shown that eosinophils are not found in all asthma tissues[30] but decreasing them 
will decrease asthma exacerbations[31]. Asthmatics who did not have the presence of 
eosinophils in airway tissues were more likely to have airway obstruction; in contrast, those with 
eosinophils had more airway remodeling[31]. Two clinical trials concluded that eosinophils may 
be involved in the pathogenesis of asthma but may not be the main “player” in the development 
and progression of the disease[31].  
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2.3 RACIAL HEALTH DISPARITIES AND SEVERE ASTHMA 
2.3.1 Racial health disparities 
Racial and ethnic health disparities exist in the United States and result in the health status of 
minorities being different than their White counterparts. These disparities are mainly driven by 
social inequities that were initially observed by W.E.B. DuBois in 1906[32]. Minorities 
disproportionately suffer from the burden of disease.  In 2005, it was reported that racial and 
ethnic health disparities resulted in approximately 83,000 deaths annually [33]. Health disparities 
for racial and ethnic minorities result in financial burdens due to the loss of income or work as a 
result of poor health. A large proportion of minorities tend to be underinsured or uninsured; 
therefore, causing them to pay high premiums or deductibles (if insured) or enduring 
discriminatory pricing (if uninsured)[32]. Uninsured patients oftentimes pay nearly double or 
triple what insured patients pay for hospital services[34]. Racial and ethnic minorities are often 
apart of publicly funded health programs are more likely to receive low quality health care which 
results in the worsening of an untreated disease and the “greater reliance on the health care 
system”[35]. Despite the arguments of those who do not believe that disparities in health care 
exist, the Institute of Medicine has shown that racial and ethnic disparities exist at every income 
level[35]. The Centers for Disease Control and the Morehouse School of Medicine have both 
made efforts to eliminate racial and ethnic health disparities; however, politicians have not made 
the elimination of health disparities a high priority[32]. Healthy People 2000 included the 
elimination of health disparities for all groups as one of their goals to be accomplished by 2010 
which resulted in $3 billion in funding from the National Institutes of Health for health 
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disparities research[25]. In 2003, the Panel on Racial and Ethnic Disparities in Medical Care 
determined that each year Blacks have excess attributable mortalities of 100,000-150,000[25].  
Access to quality care, personal health beliefs and behaviors, and patient education are all 
factors associated with health disparities but access to quality medical care is linked to access to 
health insurance[25]. Blacks are more likely to receive low quality care that is not consistent 
with practice or clinical guidelines compared to Whites. The insurance for Blacks is more likely 
to be Medicaid and Medicare has been associated with an increased risk of visiting the 
emergency department[36]. When comparing White and Black children in Medicaid, Black 
children, still, received less preventive care than White children[36]. However, a study 
conducted with asthmatic children of active duty military personnel showed that equal access to 
care can eliminate racial health disparities[37].  
2.3.2 Disparities in lung disease 
Lung disease is one area of health that has been shown to have health disparities. Asthma has 
been shown to have higher morbidity and mortality rates in Blacks than Whites[25]. Blacks, also, 
have four times the risk of hospitalization and five times the risk of mortality than Whites[12]. 
Black children visiting a private practice were less likely to report receiving a controller or 
receiver medications than White children[27]. However, Black children were less likely to 
receive care from a specialist compared to White children[38].   
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2.3.3 Disparities in physiologic measures 
Disparities in physiologic measures have also been studied. One result showed that  when 
compared to White children, Black children were more responsive to metacholine which is 
indicative of a higher level of asthma severity[39]. Also, it has been suggested that Blacks have 
smaller lung capacities and their predicted FVC and FEV1 values are 15% lower than Whites 
[39]. These values are derived from the Hankinson equation. However, these values are still 
significantly lower in Blacks[39].  
The Hankinson equation was based on 7429 nonsmoking participants from the third 
National Health and Nutrition Examination Survey (NHANES III). It provides spirometric 
reference values for three major racial groups, Whites, Blacks, and Mexicans[40]. Although this 
was a fairly large sample of people, the accuracy of the equation for non-White individuals may 
be limited due to the very small sample size of individuals in the higher age groups for the other 
races. In particular, after the age of 50 years, the sample size for Blacks drastically decreases. 
The Hankinson equation appears to be more accurate for individuals who are younger than 50 
years of age for Blacks (and Mexicans).  
Blacks have been shown to have smaller lung capacities but is the Hankinson equation 
the most accurate equation to base reference spirometric values for all races. It is important to 
note that when FEV1 is not adjusted for race, the FEV in liters is much higher for Blacks 
compared to Whites. There is nothing in the literature to suggest that one value is better to use 
than the other; however, most studies do present on the percent predicted pulmonary scores 
instead of the absolute pulmonary scores. A study with Black and White adults did reveal that 
the variability between subject in pulmonary function was larger than the difference between 
races suggesting the need for better predictive models for lung function[39]. It is not known 
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whether smaller lung capacities lead to the development of severe asthma. Nor it is known that 
the there is no other equation that is more accurate to calculate pulmonary function in Blacks, as 
well as Whites. 
2.3.4 Disparities in Severe Asthma  
In 2002, it was reported by the Centers for Disease Control and Prevention (CDC) that the 
prevalence of asthma in Blacks was approximately 38% higher than Whites. The CDC also 
reported that the asthma morbidity was drastically higher in Blacks than Whites. Compared to 
Whites, Blacks had 225% higher hospitalization rates, a 200% higher asthma death rate, 30% 
higher frequency of asthma attacks, and a 380% higher rate of visits to the emergency room[41]. 
The cause for this disparity in asthma between Blacks and Whites is unknown, however, several 
studies have suggested a possible biological or genetic reason for the increased prevalence and 
severity of asthma in the Black population. The Epidemiology and Natural History of Asthma: 
Outcomes and Treatment Regimens (TENOR) study investigated the differences in asthma 
severity between Blacks and Whites. In their study, they were able to show that Blacks were 
more likely to have severe asthma and use three or more long-term controllers, despite the fact 
that no differences in disease management were found. Black participants were also more likely 
to report not using their medication or taking medication on some days but not on all days 
resulting in Blacks having more asthma control problems. Blacks were also more likely to report 
having visited the emergency room as a result of their asthma compared to Whites, 19.6% and 
6.1%, respectively. Blacks were also shown to significantly lower quality of life scores than 
Whites[41].  
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Some studies have suggested that there is a genetic difference between Blacks and 
Whites that may account for Blacks having more severe asthma. This genetic difference could 
result in a compromised response to certain asthma medications in Blacks[41]. Other research 
has shown that mortality in Blacks is increased with the use of long-acting beta agonists (LABA) 
compared to Whites[41]. 
Past studies have shown that Blacks with asthma report their asthma symptoms 
differently than their White counterparts. Blacks primarily report upper respiratory symptoms; 
whereas, Whites report lower airway symptoms which is associated with asthma-related 
symptoms[36, 42, 43]. This is likely to lead to asthma in blacks being undiagnosed.  
2.4 RISK FACTORS AND CORRELATES FOR SEVERE ASTHMA 
2.4.1 Demographic and Socioeconomic Factors 
Female sex has been shown to be associated with asthma and adult females tend to have a more 
severe form of asthma. Some studies have shown that females have difficulty controlling their 
asthma, resulting in more hospitalizations and longer hospital stays related to their asthma[44]. 
Black race has been shown to be associated with a higher prevalence of asthma and are 
more severe asthma. It is currently unknown why Blacks have more severe asthma, although 
genetics have been suggested to play a role. Phenotype according to ancestry appears to play a 
role in the development of asthma. Individuals with African ancestry have been shown to have 
higher levels of immunoglobulin E (IgE), higher airway hyperresponsiveness, and have different 
patterns of allergic sensitization compared to those of European ancestry[11].  
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Lower income level and lower education has been shown to be associated with the 
increased prevalence of asthma[2]. Individuals living in poverty may not be as educated about 
asthma or exposure to allergens[45]. Exposure to certain indoor allergens that are suspected to 
cause asthma (cockroach dust, dust mites, mold, and cat dander) are more likely to occur in 
urban areas or inner cities which is where most low-income individuals reside.  
A study in 1997 showed that the prevalence of asthma in Black children from a low-
income family (income less than half the federal poverty level) was significantly different than 
White children. The increase in asthma prevalence among low income individuals, mainly 
Blacks, may be due to the environmental exposures that occur in urban rather than rural 
neighborhoods that increase the risk of airway hyperresponsiveness and, therefore, the 
development of asthma[2].  
Lower socioeconomic status may be a surrogate measure for other factors that may truly 
be associated with severe asthma such as poor housing, indoor allergen sensitization, 
occupational exposure[10, 25].  
2.4.2 Pulmonary Function Tests 
Declining pulmonary function or FEV1 is associated with the risk for severe asthma. One of the 
American Thoracic Society’s minor characteristics for defining severe asthma is that an 
individual have persistent airway obstruction, which is typically demonstrated by having a FEV1 
of less than 80%. Although having a low FEV1 score contributes to severe asthma, there are 
other factors that may also contribute to the development of severe asthma especially in the 
different races (e.g., Black and White race)[9].  
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The higher the percentage of reversibility of airways in response to bronchodilator use, 
the more severe the asthma. 
2.4.3 Genetics 
The etiology of asthma is unknown; however, studies have shown that asthma cannot be fully 
explained by environmental, social, cultural, or economic factors. With the availability of genetic 
mapping and the increasing popularity of genetic epidemiology in the past two decades, genetics 
has been shown to play a role in the development of asthma[11]. 
Having a family history of asthma is associated with the development of asthma; 
however, it is unclear as to whether having a family history of severe asthma is associated with 
the development of severe asthma. The population-based twin study in Norway was able to 
conclude that genetics played more of a role in the development of asthma than environmental 
factors[2]. This could possible indicate that genetics may play a role in the development of 
severe asthma. Liu et al examined NHANES data from 1999-2004 to determine the association 
of family history and the prevalence of asthma in adults. The three-tired familial risk 
methodology[46] was used to determine the whether an individual had average, moderate or high 
familial risk. Liu found that when compared to adults with average familial risk, the prevalence 
of asthma for adults with moderate familial risk was two times higher and six times higher for 
adults with high familial risk[46]. 
The Collaborative Study on the Genetics of Asthma (CSGA) was able to produce 
findings that support the claim that maternal asthma or allergy diagnosis is a risk factor for 
asthma development in children[27,46]. Also, their data suggested possible racial differences in 
the occurrence of family history of asthma with Blacks having a higher number of relatives other 
  22 
relatives with asthma. One explanation suggested is the idea that there are different frequencies 
of various alleles associated with asthma in the different racial/ethnic groups[47]. 
Unfortunately, there were a limited number of studies that have looked at the genetic link 
to asthma; therefore, it is unknown how much genetic susceptibility contributes to the 
development of asthma and the disparities in asthma[11]. The limited studies have, however, 
shown that individuals of African descent have more severe asthma than those of European 
descent[11]. It is difficult to completely understand the role that genetics plays in the 
development of asthma for Blacks due to most of the genetic studies being underpowered and the 
variety of environmental factors that are unique to Blacks. These environmental factors further 
support the theory of there being a gene-by-environment interaction associated with asthma, 
especially in Blacks. Studies have also shown that certain genes suggest this gene-by-
environment interaction.  
A meta-analysis of almost 500 studies was carried out by Ober and Hoffjan was able to 
identify approximately 79 genes that were associated with asthma or its phenotypes in two or 
more racial/ethnic groups[11]. It also shows that the vast amount of genetic studies were done in 
a European population (60%) and Asian population (28%); therefore, limiting the 
generalizability of these studies to diverse populations which suffer disproportionately from 
asthma morbidity and mortality. Unfortunately, only 3% of the genetic studies were based on 
African populations. 
Genetic studies have suggested that certain genetic polymorphisms may be associated 
with airway hyperresponsiveness and more rapid declines in pulmonary function[2, 9]. Studies 
have shown that polymorphisms of the B2-adrenergic receptor affect bronchodilator response. In 
particular these polymorphisms have been described as homozygous pairs Arg 16 Arg, Gln 27 
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Gln, and Glu 27 Glu[2]. The arginine (Arg) pair at position 16 is a polymorphism present in 
approximately 25% of Blacks and 15% of Whites[9]. There has also been studies that reported 
mutations at the interleukin 4 (IL-4) gene or the coding regions of the IL-4 receptor being 
associated with the loss of pulmonary function or near-fatal events[9]. 
CGSA was one of the first groups to screen for asthma using genome wide linkage data. 
They were also the first and only, to date, to include a population of African descent. The group 
examined the genes of families from three racial/ethnic groups: Whites, Blacks, and Hispanics. 
The study was able to show that each group had distinct genes involved with asthma and they did 
not overlap. This finding was able to provide more evidence to the genetic-by-environment 
interaction. One explanation is that there are genes unique to each race/ethnicity that contribute 
to asthma and act differently in regards to asthma development. The chromosomal regions 
involved in each group are: for Blacks (5p15, 17p11.1-q11.2), Whites (11p15,19q13), and 
Hispanics (2q33, 21q21). Another explanation is that the groups have the same polymorphisms 
but the frequency of the genes involved in asthma development is varies according to the 
racial/ethnic group[11]. The two loci unique to the Black population have been shown to be 
significantly linked to asthma: 5p15 (p=0.0008) and 17p11.1-q11.2 (p=0.0015). The 5p15 locus 
has continued to be a unique locus in just Blacks.  
Due to the mixing of various populations, including African and European ancestry, 
special attention has been paid to admixture mapping. Although availability of admixture panels 
is limited, there is still technology available to determine the risk of asthma for admixture 
populations called mapping by admixture linkage disequilibrium (MALP). The idea behind 
MALP is that when two populations are joined together that have already been isolated 
separately and due to differences in risk allele frequencies an ancestral population is 
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disproportionately affected by a specific disease, determining “genomic regions where 
individuals with the trait of interest will have a higher proportion of ancestry from the parental 
population more likely to be affected by the trait” is feasible[11]. This method is utilized to 
identify susceptible genes by mapping distortions of ancestry. However, this process is more 
successful when the differences in disease prevalence and gene susceptibility between the two 
parental populations is very large 
2.4.4 Environmental Exposure 
Exposure to allergens is known to be associated with increased airway hyperresponsiveness, 
asthma symptoms, and severe asthma. Cockroaches, dust mites, mold, cat dander, and Alternaria 
are examples of indoor exposures that have been shown to be associated with severe asthma [45]. 
Dust mites have been shown to trigger asthma attacks and more so, in urban neighborhoods. 
Positive allergen skin tests to cockroaches have also been linked to development of severe 
asthma with a higher incidence of positive skin tests in Blacks[45]. Togias et al suggested that 
there may be genetic factors that are involved with the higher sensitivity to cockroaches in the 
Black population, mainly Black population in inner cities; hence, signifying a strong association 
to environmental exposures for Blacks[47].  
Tobacco smoke or exposure to secondhand smoke is also a risk factor for severe asthma. 
In a prospective cohort study of 451 nonsmoking adults with asthma, it was shown that 
individuals with exposure to secondhand smoke had more hospitalizations, more emergency 
room visits, and higher asthma severity scores[2]. Individuals with asthma who smoke are at an 
increased risk of developing asthma and severe asthma, as well as individuals whose mothers 
smoked during pregnancy. Smoking during pregnancy was shown to decrease infant lung 
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function and lead to more asthma symptoms for the infant[45]. Cigarette smoking limits the 
effectiveness of corticosteroids which are used to treat asthma[9]; therefore, increasing the risk 
of developing severe asthma. 
2.5 COMORBIDITIES AND SEVERE ASTHMA 
2.5.1 Gastroesophageal Reflux Disease (GERD) 
Gastroesophageal reflux disease (GERD) occurs when gastric acid and contents become backed 
up in the stomach and the esophagus becomes inflamed due to this back up. The lower 
esophageal sphincter (LES) prevents the flow of gastric acid; however, some asthmatics have a 
dysfunctional LES that allows the gastric acid to flow back into the esophagus thus creating the 
symptoms associated with this condition. Over half of all asthmatics suffer from symptoms 
associated with GERD. Although this number is high, many people are misdiagnosed or do not 
receive treatment for this condition. Asthma becomes difficult to manage in an individual with 
GERD due to the condition exacerbating asthma symptoms.  
GERD can exacerbate asthma symptoms in two different ways. First, bronchoconstriction 
is encouraged by the flow of gastric acid into the esophagus through vagal stimulation. Vagal 
stimulation is also linked to chronic cough, which is commonly associated with GERD. Second, 
the microaspiration of gastric acid promotes airway inflammation and resistance. This leads to 
asthma exacerbations due to the narrowing of the airways and initiation of bronchospasms.  
Most asthmatics suffer from atypical symptoms associated with GERD such as chronic 
cough and are not aware that they are suffering from GERD but assume that it is a symptom of 
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asthma. The use of over-the-counter medication antitussive is often utilized by asthma patients to 
relieve the symptoms associated with GERD. Also, physicians are frequently not aware of the 
underlying GERD that an asthmatic patient may have due to the fact that the patient may be 
complaining about symptoms related to asthma such as a cough. An individual with severe or 
hard to control asthma is more than likely going to present with atypical symptoms of GERD.  
Various lifestyle modifications have to occur to reduce GERD symptoms, which will 
eventually reduce asthma exacerbations. Individuals with GERD should reduce their weight, 
avoid tobacco smoking and alcohol, and elevate their heads 15 degrees while sleeping[48]. 
2.5.2 Obesity 
Obesity has become a growing public health problem with approximately 1.6 billion adults and 
20 million children being overweight and 400 million adults being obese, globally[49]. Obesity 
is defined as having a body mass index (BMI) of 30 or more. There are also three subtypes of 
obesity: I (BMI=30.0-34.0), II (BMI=35.0-39.9), and III (BMI>40).  
Medical costs associated with obesity consist of almost 8.4% of the national healthcare 
expenditure with up to 100 billion dollars being spent annually to treat obesity related illnesses. 
Obesity causes morbidity and premature mortality in individuals by causing several other 
conditions such as cardiovascular disease, type 2 diabetes, gout, and cancer. Quality of life is 
also diminished in obese individuals[49].  
Obesity can cause or lead to changes in respiratory function. Respiratory mechanics, 
respiratory muscle strength, breathing patterns, and lung volumes are some of the functions that 
are disturbed by obesity[49]. Some of the lung function changes are increased respiratory rate, 
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reduced tidal volume, reduced forced vital capacity, increased airway resistance, reduced total 
lung capacity, and increased residual volume.  
The increased prevalence of concomitant asthma and obesity has led to the suggestion 
that the two may be associated with one another[49]. There have been several studied carried out 
in children and adults and retrospectively and prospectively to determine the relationship 
between asthma and obesity. The first study to suggest an association between asthma and 
obesity was released in 1984. This cross-sectional study was done in Great Britain in 1977 in a 
population of children ages 5 to 11. Several retrospective studies followed this study and 
majority of these studies showed an association between obesity and asthma in children. The first 
study to report this finding in adults was published in 1986. Several studies were able to show 
that obese adults had an increased odd of having asthma compared to those with normal BMIs. 
Surprisingly, many of the studies showed an association between obesity and asthma exclusively, 
which reveals a possible confounding effect of gender. 
In 1999, the first prospective study examining the relationship between obesity and 
asthma was published[49]. Nurses from the Nurses’ Health Study II were screened and followed 
for 4 years (1991-1995). The results of the study showed a dose-response relationship between 
BMI and the relative risk of incident asthma. The relative risk was incident asthma was 2.7 for 
obese nurses even after adjusting for confounding factors. This study was the very first study to 
state that obesity precedes or antecedes asthma. Majority of the prospective studies examining 
the relationship between obesity and asthma reported that obesity preceded the incidence of 
asthma. Eventually a prospective study in children was carried out and provided the same results 
as the adult study: obesity preceded the development of asthma. As with the retrospective 
studies, the prospective studies showed a gender bias in the relationship between obesity and 
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asthma. Females were shown to have a greater effect than men; however, this gender 
confounding has not been studied fully to definitively state a true association[49].  
2.6 ALLERGIC SENSITIZATION AND SEVERE ASTHMA 
2.6.1 Atopy 
Allergies have been shown to play a major role in the development of asthma. Asthma has been 
often described as an atopic disease, with atopy being defined as skin prick test (SPT) positivity 
or the development of IgE in response to environmental allergens. Pearce et al describes the 
paradigm between asthma and allergies as the exposure to allergen causing sensitization and 
continued exposure leading to clinical asthma[50]. A meta-analysis carried out by Pearce et al 
showed that on average there were approximately 37% of asthma cases that were attributable to 
atopy in adults[50].  
2.6.2 Immunoglobulin E 
Since IgE has been shown to be a good proxy measure of the allergic component in asthma, it is 
important to look at atopy in terms of IgE. The same meta-analysis showed that the 33% of 
asthma cases were attributable to atopy when using different cutoff levels for serum IgE[50]. 
Although atopy and asthma have been frequently studied, the relationship and its influence on 
asthma severity are complex and not well understood. In a population of only females, the results 
showed that the mean total IgE levels increased with asthma severity; however, this was not 
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statistically significant[51]. Inouye et al[52] and Siroux et al[53] also showed that there was no 
relationship between asthma severity and allergic sensitization. 
2.6.3 Racial differences in allergic sensitization 
Several studies have shown that Blacks have higher IgE levels compared to their White 
counterparts[41, 47, 36]. Black race has been highly associated with reactivity to indoor and 
outdoor allergens[41]. Blacks tend to have higher reactivity to cockroach[47, 54]. It has been 
suggested that this higher sensitization may be the result of Blacks living in inner city 
environments; therefore, there appears to be an environmental influence on the relationship 
between Blacks and allergen sensitization[47, 36]. Blacks have also been shown to be highly 
allergic to dust mite, mold, dog, cat, and rodent, which are all indoor allergens associated with 
living in urban environments[54]. Outdoor allergens such as ragweed and grass have been 
associated with Black asthmatics. Sensitization to these allergens is associated with an increased 
risk for asthma[36]. 
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Figure 1 Percentage of Phenotype Group with Five or More Positive Skin Allergen Tests in White 
Participants of the Severe Asthma Research Program 
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Figure 2 Percentage of Phenotype Group with Five or More Positive Skin Allergen Tests in Black 
Participants of the Severe Asthma Research Program 
2.7 SPECIFIC AIMS 
The overall aim of this study is to assess the extent to which the racial disparity in asthma 
is attributable to differences in the pathobiology of asthma.   
The first aim is to determine the relative contribution of differences in 
immunoinflammatory processes and environmental factors such as socioeconomic status (SES) 
to health outcome disparities in asthma between Blacks and Whites. 
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The second aim is to determine the contribution of immunoinflammatory processes and 
environmental factors to the development of high IgE, and the factors beyond IgE that contribute 
to severe asthma in Blacks. 
The third aim is to determine the policy implications of the widening racial gap in asthma 
between Black and White adult asthmatics. 
We used cross-sectional data from the Severe Asthma Research Program (SARP) to 
perform analyses for the first two research aims.  
2.8 SEVERE ASTHMA RESEARCH PROGRAM (SARP) 
In 2001, the Severe Asthma Research Program (SARP) was established by the National Heart, 
Lung, and Blood Institute to characterize and differentiate individuals with severe asthma from 
those with mild to moderate asthma. SARP initially consisted of eight funded sites- the 
University of Pittsburgh, the University of Virginia (subsites at Cleveland and Emory 
University), Brigham and Women’s Hospital, Imperial College, National Jewish Medical and 
Research Center, Wake Forest University, Washington University, and the University of 
Wisconsin, however the number of sites was reduced to 4: University of Pittsburgh, Cleveland 
Clinics (the University of Virginia and Emory included), University of Wisconsin, and Wake 
Forest University.   From August 2003 until February 2010, 1391 subjects aged 18-79 years were 
recruited and enrolled.  
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2.8.1 Defining severe asthma 
The American Thoracic Society’s (ATS) criteria were used to determine whether individuals had 
severe/refractory asthma. Table 2 below shows the major and minor criteria required to define 
severe/refractory asthma. As a note, it requires that other conditions have been excluded, 
exacerbating factors have been treated, and patient is generally compliant. 
 
Table 2 ATS workshop consensus for definition of severe/refractory asthma[9] 
Major criteria (need ??1) 
     Treatment with continuous or near continuous (??50% of year) OCSs 
     Requirement for treatment with high-dose ICSs 
Minor criteria (need ??2) 
     Requirement for additional daily treatment with a controller medication (e.g., LABA, 
theophylline, or leukotriene antagonist) 
     Asthma symptoms requiring SABA use on a daily or near-daily basis 
     Persistent airway obstruction (FEV1 < 80% predicted, diurnal peak expiratory flow 
variability > 20%) 
     One or more urgent care visits for asthma per year 
     Three or more oral steroid bursts per year 
     Prompt deterioration with a ??25% reduction in oral or inhaled corticosteroid dose 
     Near-fatal asthma event in the past 
 
2.8.2 SARP measurements 
To determine each subject’s phenotype they completed multiple allergen skin testing evaluations 
for atopy, standardized questionnaires, collection of blood, pulmonary function testing, sputum 
induction and measurement of exhaled nitric oxide. Any subject that met one of the two major 
Reprinted with permission of the American Thoracic Society. Copyright © American Thoracic Society. Sally 
Wenzel/2005/Severe Asthma in Adults/American Thoracic Society Workshop Consensus for Definition of 
Severe/Refractory Asthma figure is taken from pg 150. Official Journal of the American Thoracic Society. 
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criteria and two of the seven minor criteria were identified as severe asthmatics. However, 
subjects determined to have mild to moderate (not severe) disease remained in the study to be 
used as the reference group for comparisons/analyses. These subjects were classified as having 
mild asthma if they had a prebronchodilator FEV1 greater than 80% predicted and were on no or 
low to moderate doses of ICS; whereas, a subject was considered moderate if they had  a 
prebronchodilator FEV1 of less than 80% predicted on low to moderate doses of ICS[15].  
Current smokers or individuals with five or more pack-years of tobacco use were excluded from 
being in SARP[15].  
Along with testing for 14 common allergens, subjects were all given standardized 
questionnaires administered by clinical staff that included demographic information, medical 
history, comorbidities, family history, smoking history, and frequency of asthma symptoms such 
as wheezing, nocturnal symptoms and shortness of breath.  Medical resource or health care 
utilization was assessed by the subject’s recollection of emergency room visits, hospital and ICU 
visits, asthma ventilation procedures, and other near fatal events that may have occurred in the 
past year (12 months) or in their lifetime.  Pulmonary function testing was also carried out for 
each subject. Each subject had a variety of tests to quantify FEV1 and FVC values.   In addition, 
subjects with an FEV1 of >55% predicted underwent a methacholine challenge test to determine 
bronchial reactivity (airway twitchiness).   The PC20 was determined as the interpolated dose of 
methacholine (from the last two doses) required to cause a 20% fall in FEV1.  
Self-administered Asthma Quality of Life Questionnaires (AQLQ) were completed by the 
subjects in SARP. This 32-item questionnaire is a disease specific quality of life instrument used 
in adults with asthma to test four domains (activity limitations, symptoms, emotional function 
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and exposure to environmental stimuli).  For each domain, the total score is the mean of the 
items within the domain; whereas, the overall AQLQ score is the mean of all 32 items. 
Sputum induction was performed on about one-third of the subjects using hypertonic 
saline. Total inflammatory cell numbers were obtained. Cell differentials were performed and 
expressed as the percentage of total inflammatory cells. Bronchoscopy was conducted and 
additional pathology samples were collected. 
2.8.3 Description of Dependent and Independent Variables 
The dependent variable of interest was asthma severity (phenotype group) in both paper 1 and 2, 
but was high IgE in paper 2. Phenotype group was defined within the SARP study as mild, 
moderate, and severe. The mild and moderate groups were combined for this project; therefore, 
there are only two phenotypes being analyzed in this study, mild/moderate and severe. 
Participants with a phenotype of 1-4 were considered mild or moderate; whereas, participants 
with a phenotype of 5 were considered severe. The severe group was defined by the ATS 
workshop definition of severe or refractory asthma. 
The main independent variable of interest is racial background for paper 1. Only two 
racial groups were analyzed in the first study, Blacks and Whites.  
Several other variables were used as independent variables in the analyses: 
socioeconomic status, comorbidities, pulmonary function measures, immunoinflammatory 
markers, genetic measures, and medication use. Socioeconomic status was measured by age of 
asthma onset, employment status, exposure to secondhand smoke, pet ownership, and type of 
pet. The comorbidities in this study were diabetes, hypertension, GERD, and BMI or obesity. 
Pulmonary function measures that were used in this study were baseline predrug FEV1 % 
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predicted, baseline predrug FVC % predicted, FEV1/FVC, baseline predrug absolute FEV1 in 
liters, and maximum FEV1 reversal. Immunoinflammatory markers of interest were log10 
immunoglobulin E, presence of atopy, five or more positive allergen skin tests, type of allergen, 
area of allergen wheal, log10 eosinophils count, and log10 basophil count. Genetic measures were 
also used such as family history of asthma (no family history, one family member with asthma, 
or two or more family members with asthma) and family history of allergies (no family history, 
one family member with allergies, or two or more family members with allergies). Corticosteroid 
use (no/inhaled corticosteroid use or high dose corticosteroid/oral and injected corticosteroids) 
was used to determine medical use. 
The confounders that were adjusted for in these studies were age of enrollment or current 
age, gender and clinical center. 
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3.0  RACIAL DIFFERENCES IN BIOLOGIC PREDICTORS OF SEVERE ASTHMA: 
DATA FROM THE SEVERE ASTHMA RESEARCH PROGRAM 
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Boston, MA1, Cleveland, OH2, London, UK3, Denver, CO4, Pittsburgh, PA5, Galveston, TX6, 
Madison, WI7, St. Louis, MO8, Winston-Salem, NC9  
 
3.1 ABSTRACT 
Background: Biologic factors are known to contribute to asthma severity. It is unknown 
whether these factors differentially contribute to asthma severity in Blacks compared to Whites.  
Objective: We sought to assess the extent to which racial disparities in severe asthma between 
Blacks and Whites are attributable to physiologic, immunoinflammatory, and sociodemographic 
variables. 
Methods: Black and White asthmatic adults enrolled in a cross-sectional study focused on 
severe asthma were evaluated. Severe asthma was identified using the American Thoracic 
Society definition. Following initial univariable analyses, unconditional logistic regression 
models were used to estimate the probability of having severe asthma for Blacks and Whites.   
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Results: Differences in severe asthma in Blacks compared to Whites were observed. In 
univariable analysis, IgE was not associated with severe asthma in Blacks or Whites, while in 
multivariable analysis IgE was significantly associated with severe asthma for Blacks (p=0.014) 
but not in Whites. The odds of having severe asthma more than doubled for Blacks with 2 or 
more family members with asthma (p=0.026), while the odds of severe asthma for White 
participants with a strong family history of asthma decreased by almost half (p=0.05). Atopy was 
negatively associated with severe asthma in both races in univariable analysis, but remained 
significant only in Blacks, while co-morbidities were associated with severe asthma in Whites.  
Conclusion: Biologic factors were distinctly associated with severe asthma only in Blacks. 
Studies which incorporate comprehensive evaluation of biologic factors associated with asthma 
may lead to the development of therapies that target biologic abnormalities in Blacks.   
Key Messages: Severe asthma in Blacks is strongly associated with traditional markers of 
allergic and genetic patterns of disease. These same patterns are not seen in Whites. 
Capsule Summary: The results of this study show racial differences in the pathobiology of 
severe asthma. Compared to their White counterparts, the predisposition to more severe asthma, 
as defined by evidence for lack of control despite maximal therapy, in Blacks appears to be more 
strongly attributable to both genetic and allergic factors. These differences could lead to the 
identification of distinctly different management options for Black as compared to White 
asthmatic patients.  
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3.2 INTRODUCTION 
Although standard  treatments can control most asthma, a small number of asthmatics (about 
10%) require treatment with the highest level of inhaled corticosteroids (ICS), often in 
combination with other drugs, including systemic corticosteroids(1-2). Despite these high 
medication doses, these patients often never achieve adequate disease control  and continue to 
have  frequent and/or severe exacerbations, daily symptoms and bronchodilator use, as well as 
persistent airway obstruction (3).  Although lower lung function, a history of pneumonia, less 
atopy, and lower blood basophils have all been shown to be independently associated with the 
presence of this more severe asthma, much remains to be determined regarding the factors which 
either associate or predict its  development (4). 
Asthma in Blacks has long been associated with higher morbidity and mortality rates than 
Whites(5). Blacks have four times the risk of hospitalization and five times the risk of mortality 
than Whites(6). Although Blacks have been reported to be more likely to have severe asthma, 
particularly in relation to asthma exacerbations(7), concerns have generally focused on    
contribution from limited access to appropriate medical care, adherence to medications and 
related socioeconomic factors to this severe form of disease(8).   
However, in addition to SES, biologic factors likely also contribute to asthma severity in 
both racial groups. Whether there are differences in the contribution of biologic factors to asthma 
severity in Blacks compared to Whites has not been specifically addressed. For instance, 
immunoglobulin E (IgE) levels are well known to be significantly higher in Blacks than Whites 
in both asthmatic and non-asthmatic populations(9-16). In addition to total IgE, specific IgE also 
differs by race with higher levels of grass and cockroach specific IgE associated with asthma and 
more poorly controlled  asthma in Blacks(15, 17). Higher total IgE levels have been shown to be 
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associated with lower lung function with the relationship stronger in some racial and ethnic 
group than others (18). Finally, substantial differences in Th2 related gene allele frequencies 
have been described in Blacks compared to Whites suggesting that hereditary/genetic differences 
could explain some of the potential severity differences(19).  
The objective of this paper was to determine the extent to which the racial health 
disparities in asthma, particularly severe asthma, are attributable to physiologic, 
immunoinflammatory and/or sociodemographic variables. We hypothesized that the 
contribution of immunoinflammatory predictors to asthma severity would differ by race. To 
address this hypothesis, clinical, immunologic, and physiologic data from the cross sectional 
National Heart Lung and Blood Institutes’ sponsored Severe Asthma Research Program (SARP) 
database were analyzed to determine whether there were differences in the factors associated 
with severe asthma in Black compared to White asthmatic participants.  
3.3 METHODS 
3.3.1 Subjects 
The data in this study was obtained from subjects enrolled in the Severe Asthma Research 
Program, a network established to identify and characterize severe asthmatic subjects in relation 
to milder asthmatics to better understand mechanisms for their disease. The baseline 
characteristics of this population were recently published(4).  SARP initially consisted of eight 
funded sites- the University of Pittsburgh, the University of Virginia (subsites at Cleveland and 
Emory University), Brigham and Women’s Hospital, Imperial College, National Jewish Medical 
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and Research Center, Wake Forest University, Washington University, and the University of 
Wisconsin. The number of sites was reduced to 4 in 2006:  University of Pittsburgh (including 
National Jewish), Cleveland Clinics (including the University of Virginia and Emory 
University), the University of Wisconsin, and Wake Forest University.    
From August 2003 until February 2010, 1391 subjects aged 18-79 years were recruited 
and enrolled. Current smokers or individuals with five or more pack-years of tobacco use were 
excluded from SARP(4). The American Thoracic Society’s (ATS) definition was used to 
determine whether individuals had severe/refractory asthma(20). Severe asthma subjects were 
required to meet one of 2 major criteria (high dose inhaled or oral corticosteroid [CS] use) and at 
least 2 of 7 minor criteria. All subjects who did not meet criteria for severe asthma were 
classified as “not severe”. There were no specific requirements for the subjects other than a 
confirmed diagnosis of asthma based on symptoms, bronchodilator response or airway 
hyperresponsiveness.  
3.3.2 Data collection/Measures at interview 
All subjects completed multiple (14) allergen skin testing evaluations for atopy, standardized and 
SARP specific questionnaires, collection of blood for complete blood counts and differentials 
and total IgE, exhaled nitric oxide and  pulmonary function testing as previously described(4). 
Questionnaires were administered by clinical staff and included information on demographics, 
medical history, comorbidities, family history, smoking history, and frequency of asthma 
symptoms such as wheezing, nocturnal symptoms and shortness of breath. Medical resource or 
health care utilization was assessed by the subject’s recollection of emergency room visits, 
hospital and ICU visits, and asthma ventilation procedures. Baseline pre-bronchodilator 
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spirometry testing was carried out for each subject. In addition, a maximal bronchodilator 
response was calculated as the greatest percent change from the prebronchodilator FEV1 
following 4-8 puffs of albuterol. A variety of other procedures were done on subpopulations of 
SARP subjects (methacoline, sputum induction, and bronchoscopy), but are not included in this 
study due to incomplete data primarily based on site specific testing (sputum) or exclusions on 
the basis of FEV1% predicted (sputum, methacholine) or subject preference (bronchoscopy). 
3.3.3 Statistical Analysis 
Statistical analyses were conducted using SAS software (SAS Institute Inc. 2008. SAS Statistical 
Software: Version 9.2.Cary, North Carolina) and STATA software (StataCorp. 2009. Stata 
Statistical Software: Release 11. College Station, TX). Categorical variables were examined 
using cross-tabulations and frequencies, [expressed as n (%)]. Chi-square (?2) or Fisher’s exact 
test were performed for racial comparisons of categorical variables in the severe asthma group. 
The Wilcoxon-Mann-Whitney test was performed for racial comparisons of continuous variables 
in the severe asthma group [expressed as median (25th-75th percentiles)].  
3.3.4 Univariable models 
Unconditional logistic regression was used to calculate the crude and adjusted odds ratios to 
estimate the probability of having severe asthma. Race specific (Black and White) models were 
used for this study. Univariable models were used to determine which variables to include for 
model selection and exclude during the model building process, with only the variables with a p-
value of less than 0.15 included.  
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3.3.5 Multivariable models 
Variables that had a p-value of less than 0.15 in the univariable models were included for model 
selection. In addition, variables deemed of clinically significance regardless of statistical 
significance were included in the full model. The likelihood ratio (LR) test p-value was used to 
determine if variables should remain in the model. Goodness of fit of the model was assessed 
using Pregibon’s Dbeta and Hosmer and Lemeshow’s delta-d.  Models were adjusted for age of 
enrollment and clinical center. 
3.4 RESULTS 
3.4.1 Baseline demographics 
General demographics. Of the 1391 total enrolled in SARP, 916 participants met inclusion 
criteria for this analysis. This analysis included only adult participants (18 years of age and 
older). Participants with a racial background classified as nonblack and nonwhite, as well as 
participants considered normal (not asthmatic) were excluded (n=475). There were more White 
(71%) than Black participants (29%). More female participants were included compared to 
males, and there were slightly more mild/moderate asthmatics compared to severe asthmatics.  
Forty percent of Blacks and 42% of Whites were categorized as severe asthmatics. The median 
age at enrollment for Blacks was almost 5 years younger than the age for Whites in the severe 
asthma group (p=0.011) with 65% of Blacks enrolling into SARP at 45 years of age or younger 
(Figure 1).  While the age that the participants were first diagnosed with asthma was not 
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significantly different between Blacks and White severe asthmatics; 10% more of the Black 
compared to the White population were diagnosed younger than three years of age (Appendix 1). 
Body mass index (BMI) in Blacks was also higher than in Whites.  
Socioeconomic related factors. White severe asthmatics were more likely to be employed 
compared to their Black counterparts.  Almost 32% of Black severe asthmatics were exposed to 
secondhand smoke compared to 23% of White severe asthmatics (p=0.049). Pet ownership 
within the severe asthma group was significantly less in Blacks than Whites, with 22% of Blacks 
and 47% of Whites owning pets. 
Pulmonary function. When pulmonary function was corrected for race, height, and age 
Black asthmatics had higher median baseline predrug FEV1 and FVC % predicted values 
compared to Whites; however, absolute FEV1 (in liters) was lower for Blacks compared to 
Whites. Bronchodilator reversibility was not significantly different for Blacks and Whites. 
Immunoinflammatory markers. The mean IgE level for severe asthmatics was 174±5 
IU/ml in Blacks and 85±5 IU/ml in Whites (p=0.003). While there was no difference in overall 
prevalence of atopy in the population, Blacks were more likely to have a high number of (>5) 
positive skin tests compared to Whites. Blood eosinophils did not differ by race. 
3.4.2 Participants younger than age 40 
As Black subjects had a lower median age at enrollment, a secondary comparison was done 
between White and Black asthmatics enrolled in SARP above and below age 40. Even in those 
under 40, the mean age at enrollment for Blacks remained slightly (but not significantly) younger 
compared to Whites, 29.6 ± 6.3 and 28.7 ± 6.7, respectively. Similar to the total group, gender 
did not differ. In contrast to the total dataset, there was no significant difference in employment. 
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Even in the lower age group, BMI remained significantly and substantially higher in Blacks 
(Median=33.9; 25th-75th percentiles=30.1-45.0) than Whites (Median=27.5; 25th-75th 
percentiles=23.8-24.5). Comorbidities such as diabetes, hypertension, and GERD were not 
significantly different between races and most participants were atopic. The median IgE level in 
Black asthmatics was higher compared to Whites but the levels did not differ in the severe 
asthma subgroup. Using percent predicted values, FEV1 did not differ across the races, however, 
the absolute FEV1 (in liters) was significantly and markedly lower in Blacks (Median=1.91 liters; 
25th-75th percentiles=1.53-2.23) compared to Whites (Median=2.28 liters; 25th-75th 
percentiles=1.65-3.00), despite Blacks being younger in this subset. There was no difference in 
bronchodilator reversibility. 
 
3.4.3 Participants age 40 and above 
Among older asthmatics, Black severe asthmatics were significantly younger and younger at 
diagnosis than White severe asthmatics.  Greater than 10% more Black severe asthmatics were 
female than Whites, p=0.07. Current employment again did not differ among the races. White 
asthmatics were more likely to report a diagnosis of GERD compared to Blacks (45% and 33%, 
respectively) despite the higher BMI in the older Black severe asthmatics. There were no 
differences in atopic/allergic markers across the two races.   
Similar to the younger age group, baseline pre drug FEV1, FVC % predicted and the 
FEV1 /FVC were significantly higher in Blacks compared to Whites. The absolute FEV1 (in 
liters) did not differ between Blacks and Whites in this age group, but was likely confounded by 
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the higher percentage of females and lower overall age in the Black participants. Bronchodilator 
reversibility did not differ between the races.  
3.4.4 Univariable models: Black participants 
In the univariable models for Blacks, current age and pulmonary function (baseline predrug 
FEV1 in liters, baseline predrug FEV1 %predicted) were highly associated with asthma severity. 
BMI, GERD, and current employment were also associated with severe asthma, but no other co-
morbidity was associated, including exposure to second hand smoke. Interestingly, the presence 
(atopy yes/no) and degree of atopy (% of participants with five or more positive allergen skin 
tests) were negatively associated with severe asthma, while 2 or more family members with 
asthma was positively associated. In the univariable analysis, IgE was not associated with severe 
asthma in Blacks.  
3.4.5 Univariable models: White participants 
The results from the White univariable models differed substantially from the Black 
univariable models. While current age, BMI, GERD and pulmonary function (baseline pre drug 
FEV1 in liters and percent predicted) were statistically significant in these models, in Whites, 
other co-morbidities, such as diabetes and hypertension, were highly associated with asthma 
severity. However, similar to Blacks, second hand smoke exposure was not associated. In 
contrast to Blacks, older age when first diagnosed with asthma and increasing degree of 
bronchodilator responsiveness were also highly associated with asthma severity. Similar to 
Blacks, the presence and degree of atopy were also negatively predictive of severe asthma.  
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Unlike Blacks, owning a pet was marginally associated with decreased odds for severe asthma in 
Whites. Family history of asthma was not associated with asthma severity in Whites. 
3.4.6 Multivariable models: Black participants 
For every 10% decrease in baseline FEV1 % predicted the odds of having severe asthma 
increased 40% (p<0.0001).Although bronchodilator responsiveness was of borderline 
significance (p=0.058), the odds for severe asthma decreased by 2% with an increase of one 
percent in reversibility after bronchodilator suggesting that those Black asthmatics with more 
fixed airflow limitation were at highest risk of severe asthma. 
In contrast to the univariable analysis, IgE was strongly associated with severe asthma in 
Blacks (p=0.014). For every log10 increase in IgE the risk of severe asthma more than doubled. 
The odds of having severe asthma  also more than doubled for Blacks who had  2 or more family 
members diagnosed with asthma (p=0.026). Despite the association with total IgE and family 
history, having five or more positive skin tests to allergens was negatively associated with severe 
asthma (p=0.05).  
Blacks with GERD have more than three times the odds of having severe asthma 
compared to Blacks without GERD (p=0.002). While employment was marginally associated 
with severe asthma in the univariable models, it was not significant in the multivariate analyses 
(p=0.366). 
After adjusting for confounders, baseline predrug FEV1 % predicted, GERD, total IgE, 
and having two or more family members with asthma remained significantly associated with 
asthma severity. Given the relatively smaller sample size of Black participants, lower 
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bronchodilator responsiveness and having less than five positive skin tests may also be 
considered significant in this model.    
3.4.7 Multivariable models: White participants 
Similar to Blacks, baseline FEV1% predicted was highly associated with severe asthma, with   
every 10% percent decrease in baseline FEV1 increasing the odds of having severe asthma by 
60% (p<.0001). Additionally, GERD remained highly associated with severe asthma (doubling 
the odds of severe asthma) (p=0.009), while in contrast to Blacks, diabetes remained marginally 
associated with asthma severity (p=0.114). Current pet ownership decreased the odds of severe 
asthma by 35% (p=0.05). In contrast to Black severe asthmatics, the odds of severe asthma for 
White participants who had 2 or more family members diagnosed with asthma decreased by 
almost half (p=0.05) and IgE (and measures of atopy) did not enter the final model. The final 
model for Whites after adjusting for age and site included baseline FEV1 percent predicted, 
GERD,  lack of pet ownership  and having no or a weak family history of asthma  as positive 
predictors of asthma severity.  
3.5 DISCUSSION 
In this cross sectional analysis of over 900 Black and White asthmatic subjects, striking 
differences were found in the factors associated with severe asthma. While baseline FEV1 % 
predicted and GERD were important factors for both racial groups, biologic factors including 
IgE, skin test reactivity and family history were distinctly associated with severe asthma in 
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Blacks. Although socioeconomic factors almost certainly impact the high health care utilization 
and associated morbidity of asthma in Blacks, the results from this analysis suggest 
biologic/genetic factors related to atopy/allergy are, also, of substantial, if not even greater 
importance. These results underline the importance of understanding differences in pathobiologic 
mechanisms driving asthma and its severity in different racial groups.   
Asthma has often been described as an atopic disease, with atopy defined as the 
development of specific IgE in response to environmental allergens. However, the association of 
allergies with asthma severity has been more difficult to confirm. Indeed, in the initial  SARP 
demographic study, the presence of atopy was a strong negative predictor for severe asthma(4).  
Therefore, the finding that increasing IgE levels were strongly predictive of severe asthma in 
Blacks (and not at all in Whites) was surprising. While IgE was not a significant predictor of 
severity in the univariable model for Blacks (p=0.717); it became a strong predictor of severity in 
the multivariate model, suggesting that when numerous confounding factors were controlled for 
IgE remained as a predictive variable (p=0.016). Black asthmatics were again confirmed to have 
a much higher total IgE compared to White asthmatics, irrespective of severity. These results 
extend the findings of Naqvi et al who demonstrated that higher IgE levels were associated with 
more severe asthma in Black, Mexican, and Puerto Rican patients(18). However, unlike the 
study by Naqvi, SARP used a rigidly predefined and validated definition of severity, which 
supports the relevance of this biologic difference to disease severity. Naqvi utilizes frequency of 
symptoms and FEV1 % predicted scores to categorize a participant as moderate-to-severe; 
whereas, SARP requires that a participant be continuously using an oral or high dose inhaled 
corticosteroid. 
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While IgE was a significant positive predictor of asthma severity in Blacks, having five 
or more positive skin tests was a significant negative predictor of severe asthma. It is still unclear 
why two measures of atopy have apparently opposing effects on asthma severity within the 
Black SARP population. Serum IgE, which is a sum of all the circulating systemic IgE, would 
appear to be measuring something additional to the presence or absence of the 14 specific IgEs 
measured by skin testing in SARP. Interestingly, a subsequent post hoc univariate model also did 
not find a positive skin test for cockroaches to be associated with severe asthma in Blacks 
(p=0.60). While further pathobiologic studies of this relationship are needed, the data suggest 
that it may not be the number of positive skin tests, rather the amount of specific IgE made to 
each or any allergen or the presence of a specific, yet unidentified IgE. In future studies, the total 
wheal size to each allergen can also be included in the analyses. Additionally, robust measures of 
allergen exposure were not included in these studies, which could also contribute to these 
differences.    
A well known risk factor for asthma is having a first degree relative with asthma(21). 
Atopy and allergy are also known to be contributed to by hereditary/genetic factors. Therefore, 
while it might be expected that family history would be predictive for asthma, studies on the 
hereditary relationship to severity in specific racial groups (as opposed to presence) have been 
limited. Perhaps more surprisingly, a reasonably strong family history of asthma in White 
participants was negatively associated with severe asthma.  Given the generally later age at onset 
in the White participants (especially in those >40 yrs old), these results suggest that severe 
asthma in Whites specifically includes a different, non-atopic/allergic, late onset disease 
subset/phenotype with less genetic elements, as has been previously identified(22). This specific 
subtype/phenotype of severe asthma is not being identified in Blacks either because it is less 
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likely to occur or it is not being identified possibly for socioeconomic related reasons. In any 
case, studies of Black asthmatic populations may be more likely to produce genetic links to 
severity as compared to studies of White populations. 
Numerous studies have pointed to the critical role that socioeconomic factors and health 
disparities play in asthma in the Black community. In the current study, factors related to SES, 
including current employment and pet ownership, were not related to severe asthma in Blacks. 
However, this lack of relationship to SES may be related to the limited data collected in SARP 
related to SES. As SARP expands, the questionnaires have added educational, marital status and 
zip code, which should improve the ability to assess the role of SES in the severity of asthma.  
Interestingly, while employment status was not associated with severity in either Blacks or 
Whites, as has been noted previously, pet ownership was associated with protection from severe 
asthma in Whites(23). Black participants in SARP, in general, had significantly lower pet 
ownership than Whites in SARP.  It is unclear whether increasing pet ownership would improve 
asthma outcomes in Blacks (as seen in Whites), even without substantial changes in SES, but 
requires further study.    
Univariable models revealed that comorbidities were highly associated (p<0.0001) with 
asthma severity in Whites. This association was much less in Blacks except for GERD, which, as 
previously shown in SARP, continued to be a positive predictor of severity for  both Blacks and 
Whites. In contrast, hypertension and diabetes were highly significant predictors for Whites but 
not for Blacks, despite their higher prevalence in Blacks compared to Whites in the general 
population.  It can be hypothesized that asthma itself may be affecting Blacks much more than 
Whites such that the severity of the asthma could be masking the effects of other diseases. 
Blacks may be focusing on the most severe ailments, while other diseases may not yet be 
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diagnosed. Blacks may have been diagnosed younger with asthma due to a better pediatric 
medical safety net, or because Black babies with asthma are substantially sicker than White 
babies with asthma.  As they age, Blacks may not be going to the doctor regularly to get full 
checkups, which would allow diagnosis of comorbidities, such as diabetes. In support of this, 
Black severe asthmatics reported lower percentages of diagnosed diabetes and hypertension 
compared to Whites; while Blacks with mild/moderate asthma reported diabetes and 
hypertension twice as often as their White counterparts. Exposure to tobacco smoke has also 
been shown to increase the prevalence and severity of asthma. In a cohort of adult nonsmoking 
asthmatics, adults exposed to secondhand smoke at baseline had higher asthma severity scores 
compared to those without tobacco smoke exposure(24). However, in SARP, secondhand smoke 
was not a significant predictor of asthma severity for either race and was, therefore, not included 
within the final predictor model for both races.  
Lower  baseline predrug FEV1 is well recognized as a  predictor of severe asthma(3, 20, 
25). In this study, the odds of severe asthma increased by 40% and 60% for Blacks and Whites, 
respectively, for every 10% decline in FEV1 % predicted. While we used FEV1 % predicted in 
the models, there are also striking differences in the absolute FEV1 (in liters) in Blacks compared 
to Whites, which are “corrected” by the Hankinson equations used in SARP lung function 
testing.   When racially corrected (and age/sex corrected) the mean/median FEV1 % predicted is 
higher in Blacks compared to Whites. However, the absolute FEV1 is significantly lower 
compared to Whites, despite the younger age of the Black asthmatics. Hankinson equations for 
FEV1 % were built on disproportionate samples sizes in Blacks compared to Whites. White 
participants are equally distributed throughout the age groups; whereas, after the age of 50 years 
the number of Black participants drastically decreases compared to the number of younger Black 
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participants(25). As a Black participant ages and goes beyond the age of 50 years, the accuracy 
of the Hankinson equations may not be as valid as they are for the younger Black participants.  
Further, recent genetic studies suggest that being identified as “Black” in America is 
accompanied  by a wide range of genetic racial admixture ranging from 100% African ancestry 
to 10% or less, such that predictive equations for  “Blacks” may not apply to all “Black” 
participants(26). In any case, measuring lung function by FEV1 % predicted could easily 
overestimate the lung capacity of many Black patients and lead to under recognition of the 
severity of the disease.   
In Blacks, in addition to FEV1 % predicted, maximum bronchodilator responsiveness was 
marginally associated with asthma severity in Blacks. However, for every % increase in 
bronchodilator responsiveness the odds for severe asthma decreased by 2%.  The reasons for this 
inverse relationship are not clear but suggest that as asthma worsens in Blacks, the airways may 
stiffen/remodel such that the most commonly used treatment for asthma (beta agonists) becomes 
less effective.  Whether these findings suggest a mechanism for the recent findings regarding 
increased severe asthma exacerbations and deaths in Blacks taking long acting beta agonists 
remains to be determined(27).   
This study is not without limitations, certainly the biggest of which is the cross-sectional 
study design. It is difficult to confirm a temporal relationship in regards to severity and the 
variables of interest. Another limitation is the sample size differences for each race. The White 
SARP population consisted of over 70% of the data in this analysis, whereas, less than 30% of 
the data is from the Black SARP population. Having populations of similar sizes would aid in 
confirming the results from this study and possibly reveal stronger associations between 
predictors and severe asthma.  Although the SARP database is one of the most extensive 
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databases of asthmatics from numerous geographic sites and includes the collection of lung 
inflammatory markers, such as sputum eosinophils, sputum induction was only performed on 
about 50% of the population.   Therefore, sputum measures could not be used. However, genome 
wide association data and longitudinal participant information are being added to the database 
enabling even more complete studies on asthma severity in the future. 
In conclusion, distinctly different factors appear to be associated with rigidly defined 
severity of asthma in Blacks compared to Whites, with allergic markers and strong family history 
much stronger positive predictors of severity for Blacks than for Whites.  Thus in addition to 
socioeconomic factors, studies which incorporate comprehensive evaluation of biologic and 
genetic factors of relevance to asthma in  Blacks in particular, may lead to the development of 
targeted therapies which improve overall asthma outcomes in the Black population.  
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3.7 TABLES AND FIGURES 
Table 3 Univariable Logistic Regression Models for Black Participants in SARP (n=267) 
Variable Coeff SE OR 95% CI G p 
Age Onset 0.006 0.0090 1.01 0.99-1.02 0.45 0.503 
Age 0.057 0.0119 1.06 1.03-1.08 22.63 <.0001 
Female 0.176 0.2745 1.19 0.70-2.04 0.41 0.521 
Center -0.112 0.0462 0.89 0.82-0.98 5.83 0.016 
BMI 0.033 0.0142 1.03 1.01-1.06 5.36 0.021 
Employed -0.376 0.2559 0.69 0.42-1.13 2.16 0.141 
2nd Smoke -0.205 0.2660 0.82 0.48-1.37 0.59 0.442 
Pets 0.042 0.3008 1.04 0.58-1.88 0.02 0.889 
GERD 0.977 0.2865 2.66 1.52-4.66 11.63 0.001 
Diabetes 0.647 0.4681 1.91 0.76-4.78 1.91 0.167 
HTN 0.409 0.2988 1.51 0.84-2.70 1.87 0.171 
FEV1% pred -0.031 0.0066 0.97 0.96-0.98 22.07 <.0001 
FEV1 liters -1.397 0.2312 0.25 0.16-0.39 36.54 <.0001 
% Eosinophil 0.007 0.0351 1.01 0.94-1.08 0.04 0.849 
Reversal 0.0067 0.0061 1.01 0.995-1.02 1.18 0.277 
IgE 0.075 0.2077 1.08 0.72-1.62 0.13 0.717 
????????????? -0.486 0.2843 0.62 0.35-1.07 2.92 0.088 
Atopy -1.009 0.2855 0.37 0.21-0.64 12.50 0.0004 
1 Fam Hx -0.065 0.3090 0.94 0.51-1.72 0.04 0.834 
2+ Fam Hx 0.511 0.3166 1.67 0.90-3.10 2.61 0.106 
*Age Onset=Age when first diagnosed with asthma, Age=Age when enrolled into SARP, Center= clinical center 
site, 2ndhand smoke=exposure to secondhand smoke during day, Pets=own any pets, GERD=gastroesophogeal 
reflux disease, HTN=hypertension diagnosis, FEV1=forced expiratory volume in one second, % Eosinophil=% of 
eosinophils in the blood, Reversal=Max FEV1 reversal, IgE=Immunoglobulin E, ??????????????????????????????????
skin tests, 1 Family Hx= Have 1 family member with asthma, 2+ Family Hx= Have 2 or more family members with 
asthma 
* IgE entered as continuous log-transformed variables in the model 
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Table 4 Univariable Logistic Regression Models for White Participants in SARP (n=649) 
Variable Coeff SE OR 95% CI G p 
Age Onset 0.015 0.0054 1.02 1.00-1.03 7.61 0.006 
Age 0.057 0.0067 1.06 1.05-1.07 72.70 <.0001 
Female -0.261 0.1656 0.77 0.56-1.07 2.48 0.115 
Center -0.138 0.0289 0.87 0.82-0.92 22.68 <.0001 
BMI 0.044 0.0115 1.05 1.02-1.07 14.64 0.0001 
Employed 0.037 0.1660 1.04 0.75-1.44 0.05 0.823 
2nd Smoke 0.106 0.1930 1.11 0.76-1.62 0.30 0.584 
Pets -0.309 0.1621 0.73 0.53-1.01 3.63 0.057 
GERD 1.116 0.1827 3.05 2.13-4.37 37.30 <.0001 
Diabetes 1.420 0.3793 4.14 1.97-8.70 14.02 0.0002 
HTN 1.198 0.2319 3.31 2.10-5.22 26.67 <.0001 
FEV1% pred -0.066 0.0055 0.94 0.93-0.95 145.77 <.0001 
FEV1 liters -1.399 0.1264 0.25 0.19-0.32 122.56 <.0001 
% Eosinophil -0.010 0.0304 0.99 0.93-1.05 0.10 0.748 
Reversal 0.029 0.0055 1.03 1.02-1.04 27.14 <.0001 
IgE -0.124 0.1399 0.88 0.67-1.16 0.79 0.374 
????????????? -0.488 0.1962 0.61 0.42-0.90 6.17 0.013 
Atopy -0.654 0.1734 0.52 0.37-0.73 14.25 0.0002 
1 Fam Hx -0.246 0.1874 0.78 0.54-1.13 1.72 0.190 
2+ Fam Hx -0.096 0.2103 0.91 0.60-1.37 0.21 0.648 
*Age Onset=Age when first diagnosed with asthma, Age=Age when enrolled into SARP, Center= clinical center 
site, 2ndhand smoke=exposure to secondhand smoke during day, Pets=own any pets, GERD=gastroesophogeal 
reflux disease, HTN=hypertension diagnosis, FEV1=forced expiratory volume in one second, % Eosinophil=% of 
eosinophils in the blood, Reversal=Max FEV1 reversal, IgE=Immunoglobulin E, ??????????????????????????????????
skin tests, 1 Family Hx= Have 1 family member with asthma, 2+ Family Hx= Have 2 or more family members with 
asthma 
* IgE entered as continuous log-transformed variables in the model 
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Table 5 Final Model for Black Participants in SARP (n=267) 
Variable OR 95%CI p>|z| 
Age 1.06 1.02-1.09 0.002 
Center 0.93 0.81-1.07 0.318 
Employed 0.72 0.35-1.48 0.366 
1 Family history 1.50 0.62-3.60 0.367 
2+ Family history 2.79 1.13-6.87 0.026 
GERD 3.59 1.62-7.97 0.002 
Baseline FEV1% pred 0.96 0.94-0.98 <.0001 
Max FEV1 Reversal 0.98 0.96-1.00 0.058 
IgE 2.12 1.16-3.87 0.014 
?????????????????????? 0.46 0.21-1.01 0.053 
* Age=Age when enrolled into SARP, Age Onset=Age when first diagnosed with asthma, Center= clinical center 
site, 1 Family History= Have 1 family member with asthma, 2+ Family History= Have 2 or more family members 
with asthma, GERD=gastroesophogeal reflux disease, FEV1=forced expiratory volume in one second, 
IgE=Immunoglobulin E 
* IgE entered as continuous log-transformed variable in the model 
*Adjusted for current age (age of SARP enrollment) & clinical center 
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Table 6 Final Model for White Participants in SARP (n=649) 
Variable OR 95%CI p>|z| 
Age 1.02 1.00-1.04 0.046 
Center 0.88 0.81-0.95 0.001 
BMI 1.00 0.98-1.03 0.790 
Age Onset 1.00 0.99-1.02 0.866 
1 Family History 0.67 0.42-1.09 0.108 
2+ Family History 0.57 0.32-1.00 0.051 
Pets 0.65 0.42-1.00 0.051 
GERD 1.92 1.18-3.13 0.009 
Diabetes 2.27 0.82-6.29 0.114 
Baseline FEV1% pred 0.94 0.93-0.95 <.0001 
* Age=Age when enrolled into SARP, Center= clinical center site, Age Onset=Age when first diagnosed with 
asthma, 1 Family History= Have 1 family member with asthma, 2+ Family History= Have 2 or more family 
members with asthma, Pets=own any pets, GERD=gastroesophogeal reflux disease, FEV1=forced expiratory 
volume in one second 
*Adjusted for current age (age of SARP enrollment) & clinical center 
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Figure 3 Percent of Black & White Participants enrolled into the Severe Asthma Research Program 
by age at enrollment 
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Figure 4 Percent of Black & White Population diagnosed with asthma in the Severe Asthma 
Research Program 
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4.0  THE PREDICTORS OF TOTAL SERUM IMMUNOGLOBULIN E IN BLACK 
ADULT ASTHMATICS IN THE SEVERE ASTHMA RESEARCH PROGRAM 
4.1 INTRODUCTION 
Severe asthma occurs in approximately 10% of those with asthma[1, 2]. Racial disparities appear 
to exist within the severe asthma population, Blacks often presenting with poorly controlled and 
more severe asthma as compared to their White counterparts[3]. Nationally, the mortality rates 
for asthma in Blacks range from two to five times those observed in Whites[4, 5]. It is very likely 
that a combination of genetics, the environment, and socioeconomics all play a role in this 
disparity[3, 5].  
 Immunoglobulin E (IgE) is a proxy measure of atopy and studies have shown that Blacks 
have higher IgE levels compared to Whites[3, 5, 6]. Total serum IgE was recently shown to be a 
risk factor for severe asthma in Blacks, but not in Whites. While total IgE has a hereditary 
component, multiple environmental and genetic factors are likely to contribute[7, 8]. Exposure to 
particular allergens, including D. pteronyssinus, cockroach, and Alternaria, has been strongly 
associated with the development of specific IgE. In Black children specific IgE to cockroach is 
known to be a risk factor for hospitalizations and days missed from school for asthma[9]. Its 
presence appears to require both a level of environmental exposure and genetic tendency to 
production of IgE[10]. However, whether specific IgE relate to severe asthma, as opposed to 
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poorly controlled (and perhaps undertreated) asthma is not yet clear[11-13]. Interestingly, 
sensitization to grass and ragweed have also been reported to be more likely in Black 
children[14]. These outdoor allergens in particular are often associated with extremely high 
levels of specific IgE that likely contribute substantially to the total measured IgE. However, 
whether they contribute to the total IgE associated with severe asthma in Blacks is not yet 
known.    
In our previous study, family history of asthma was strongly predictive of severe asthma 
in association with IgE.  Thus, in addition to IgE, genetics almost certainly plays a major role in 
the development of asthma, and more recently in Blacks with severe asthma[3, 5]. The 
Collaborative Study on the Genetics of Asthma (CSGA) revealed that Blacks, in particular, had a 
stronger family history of asthma as compared to Whites and concluded that the higher number 
of family members diagnosed with asthma in Blacks may reflect the “contribution of certain 
alleles with difference frequencies”, as well as  early exposures of Blacks to allergens[15].      
As our previous study suggested that a higher IgE was a predictor of severe asthma in 
Blacks as compared to Whites[3], an analysis of the factors that predict a high IgE level in all 
Black asthmatics, as well as in those with severe disease was undertaken. As high IgE alone was 
not specific for severe asthma, a 2nd analysis was undertaken to identify the additional factors, 
which in the presence of high IgE associate with the development of severe asthma. To address 
these objectives, clinical, immunologic, and physiologic data from the cross-sectional National 
Heart Lung and Blood Institutes’ sponsored Severe Asthma Research Program (SARP) database 
were analyzed in relation to IgE levels and asthma severity.  
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4.2 METHODS 
4.2.1 Subjects 
All data was obtained from subjects enrolled in the Severe Asthma Research Program, a network 
established to identify and characterize severe asthmatic subjects in relation to milder asthmatics 
to better understand mechanisms for their disease.  The baseline characteristics of this population 
were recently published[3, 16]. SARP initially consisted of eight-funded sites- the University of 
Pittsburgh, the University of Virginia (subsites at Cleveland and Emory University), Brigham 
and Women’s Hospital, Imperial College, National Jewish Medical and Research Center, Wake 
Forest University, Washington University, and the University of Wisconsin. The number of sites 
was reduced to 4 in 2006: University of Pittsburgh (including National Jewish), Cleveland 
Clinics (including the University of Virginia and Emory University), the University of 
Wisconsin, and Wake Forest University. Current smokers or individuals with five or more pack-
years of tobacco use were excluded from SARP. This study was approved by the IRB affiliated 
with the University of Pittsburgh Medical Center. 
From August 2003 until July 2010, 1391 subjects aged 18-79 years were recruited and 
enrolled, while 955 were White and Black participants had complete demographic and 
phenotypic information. The American Thoracic Society’s (ATS) definition of severe asthma 
was used to determine whether individuals had severe/refractory asthma[1]. All subjects who did 
not meet criteria for severe asthma were classified as “not severe”. Of the participants enrolled in 
SARP, 278 Black participants 18 yrs of age and older met criteria for not severe or severe asthma 
Participants with missing IgE data were excluded (n=69).    
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4.2.2 Data Collection/Measures at Interview 
All subjects completed multiple (14) allergen skin testing evaluations for atopy, standardized and 
SARP specific questionnaires, collection of blood for complete blood counts and differentials 
and total IgE, exhaled nitric oxide and pulmonary function testing as previously described. 
Questionnaires were administered by clinical staff and included information on demographics, 
medical history, comorbidities, allergic exposures (own dog/cat, specific allergen sensitivity) 
family history, and smoking history, atopy (yes or no) was defined as a single positive reaction 
(consisting of a wheal at least 3mm in diameter and erythema of at least 10mm diameter) to any 
of 14 skin test allergens. The area of the wheal, calculated as the widest diameter of the wheal 
multiplied by the largest perpendicular wheal length for each allergen tested was calculated as an 
estimate of amount of specific IgE to a given allergen.  Obesity was defined as participants with 
a body mass index (BMI) of greater than 30. 
Baseline pre-bronchodilator spirometry testing was carried out for each subject. In 
addition, a maximal bronchodilator response was calculated as the greatest percent change from 
the prebronchodilator FEV1 following 4-8 puffs of albuterol. A variety of other procedures were 
done on subpopulations of SARP subjects (methacoline, sputum induction, and bronchoscopy), 
but are not included in this study due to incomplete data primarily based on site specific testing 
(sputum) or exclusions on the basis of FEV1% predicted (sputum, methacholine) or subject 
preference (bronchoscopy).  
  69 
4.2.3 Statistical Analysis 
Statistical analyses were conducted using SAS software (SAS Institute Inc. 2008. SAS Statistical 
Software: Version 9.2.Cary, North Carolina) and STATA software (StataCorp. 2009. Stata 
Statistical Software: Release 11. College Station, TX). Categorical variables were examined 
using cross-tabulations and frequencies, [expressed as n (%)]. Chi-?????????2) or Fisher’s exact 
test were performed for racial comparisons of categorical variables in the severe asthma group. 
The Wilcoxon-Mann-Whitney test was performed for racial comparisons of continuous variables 
in the severe asthma group [expressed as median (25th-75th percentiles)].  
4.2.4 Univariable Models 
Unconditional logistic regression was used to calculate the crude and adjusted odds ratios to 
estimate the probability of having a high IgE in general, and then having a high IgE in severe 
asthma. IgE group specific (low and high) models were used for this study. The median IgE for 
this population was used to determine the high and low IgE group. Participants with an IgE level 
below the median were classified as “low” while participants with an IgE level at or above the 
median were classified as “high”.  Univariable models were used to determine which variables to 
include for model selection and to exclude during the model building process, with only the 
variables with a p-value of less than 0.15 included. Variables with a p-value of less than 0.05 
were considered highly significant.  
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4.2.5 Multivariate Models 
Variables with a p-value of less than 0.15 in the univariable models were included for model 
selection. Forward stepwise model selection was used to determine the variables within the 
models. Goodness of fit of the model was assessed using Pregibon’s Dbeta and Hosmer and 
Lemeshow’s delta-d.  Models were adjusted for age of enrollment (current age), clinical center, 
and gender. Variables with a p-value of less than 0.05 were considered significant. 
4.3 RESULTS 
4.3.1 Demographics 
Demographics:  All Black asthmatics by High and Low IgE  (Table 1)  
The median age at onset was lower in the high as compared to the low IgE group 
(p=0.017).  Body mass index (BMI) was high for all Blacks, but higher in those with low IgE 
compared to those with high (p=0.058). There was a marginal difference in the diagnosis of 
diabetes between the IgE groups with the low IgE group tending to have more diabetes than the 
high group (p=0.051). Employment rates did not differ between the high and low IgE groups. 
Demographics:  Black Severe Asthmatics by High and Low IgE (Table 2)  
Among the Black severe asthmatics, 47.4% were in the low IgE group and 52.6% were in 
the high IgE group. However, unlike the total population, there was no difference in age at onset 
between low and high IgE subgroups (p=0.462). Further, there was no difference in diabetes 
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diagnosis in severe asthmatics with and without high IgE. Similar to the total population, there 
was no difference in rates of employment in those high and low IgE.    
Allergic Immune factors in All Asthmatics (Table 1)  
Not surprisingly, participants in the high IgE group were more likely to be atopic and had 
more positive allergen skin tests compared to the low IgE group. Atopy was common in all 
Black asthmatic subjects, with nearly 90% of participants in the high IgE group atopic compared 
to almost 80% in the low IgE group (p=0.016). Asthmatic participants in the high IgE group 
were more likely to have multiple positive skin tests, including almost all the common indoor 
and outdoor allergens. 59% of all Black asthmatics with high IgE had 5 or more positive skin 
tests, while 28% of those in the low IgE group had 5 or more (p<0.001). The allergen that most 
significantly differed between high and low IgE subjects was grass mix (66% and 38% positive 
respectively, p<0.0001). In addition to “presence of a positive reaction”, the median allergen 
wheal areas for multiple indoor and outdoor allergens were all significantly larger for the high 
IgE group compared to the low IgE group, with the largest wheals seen in response to grass and 
dust mite.  Environmentally, pet ownership tended to be more likely in those with high IgE 
(p=0.09 for any pet, p=0.02 for furry pet other than cat or dog). Consistent with this more 
allergic phenotype, blood eosinophil counts were significantly higher in the high IgE group 
(p=0.002).  Interestingly, while family history of allergies did not differ between the two group, 
the percentages of patients reporting this was numerically higher in the low IgE group (p-values 
<0.2).  There were no differences in family history of asthma.  
Allergic Immune factors in the Severe Asthma Population (Table 2)  
As previously noted, atopy was less common in the Black severe asthmatics than in the 
total population irrespective of IgE.  In contrast to all asthmatics, in severe asthmatics, there were 
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no differences with the presence of atopy by high or low IgE (p=0.497) and the percentage of 
participants with >5 positive skin tests was only marginally different (p=0.057). The high IgE 
severe asthma group was more likely to have positive skin tests for grass mix, ragweed, 
cockroach and D. pteronyssinus. Only the median areas for D. pteronyssinus and ragweed were 
greater in those asthmatics with high IgE, and all median wheal areas were markedly smaller 
than those in all Black asthmatics (for example, ragweed median in all asthmatics=38, median in 
severe asthmatics=0).  In contrast to the total asthma population, there were no differences in pet 
ownership by IgE level. Similar to the differences in the total asthma population, blood 
eosinophil counts were also higher in the high IgE severe asthma group (p=0.045). In contrast to 
the total asthma population, there were no numeric or statistical differences between family 
history of allergies or asthma by level of IgE. 
Pulmonary function in the All Asthmatics (Table 1)  
While there were no differences in either FEV or FVC% predicted, the high IgE group 
had a significantly lower FEV1 /FVC compared to the low IgE group (p=0.0003). Bronchodilator 
reversibility was also significantly higher in the high IgE group than in the low IgE group.  
Pulmonary function in the Severe Asthma Population (Table 2)  
Similar to all Black asthmatics, FEV1/FVC and bronchodilator reversibility tended to be 
lower in the high IgE group (p=0.088 and p=0.072, respectively).  
Corticosteroid use in the Severe Asthma Population (Table 2) 
Systemic corticosteroid (CS) use was not significantly different between the high and low 
IgE group for Black severe asthmatics (p=0.1860). Half of the low IgE groups used systemic CS 
compared to 35% in the high IgE group. 
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4.3.2 Univariable Models 
Factors predicting High IgE in All Asthmatics (Table 3a)  
The presence of atopy or multiple positive skin tests (5 or more) each triples the risk of 
having high IgE in all Black asthma participants (p<0.0235, p<0.0001). Specific positive skin 
reactions to the outdoor allergens grass mix and ragweed in all Black participants increased the 
likelihood of being in the high IgE group by 3.5 fold and 3-fold respectively (p<0.0001 and 
p=0.0002). Positive allergen skin tests to indoor allergens such as cockroach and D. 
pteronyssinus, also increased the risk but to a smaller (2-fold) degree than outdoor allergens 
(p=0.006 and p=0.0009 respectively). Reactions to trees also doubled the risk, p= 0.0110. The 
area of the wheal for various allergens (Alternaria, grass mix, cat, dog, cockroach, D. 
pteronyssinus, tree, and ragweed) increased the odds of being in the high IgE group by about 1% 
for every 1 mm2 change. Pet ownership tended to increase the odds of having a high IgE 
associated asthma (p=0.09), and having a furry pet, other than a dog or cat, increased the odds of 
having a high IgE more than 5-fold.  
The diagnosis of diabetes marginally decreased the odds of being in the high IgE group 
by 70% (p=0.061), while obesity had no impact (p=0.1792). Family history of allergies tended to 
decrease the odds of having high IgE by about 40% (p-values<0.2) while family history of 
asthma was not significantly associated.  
Factors predicting High IgE in the Severe Asthma Population (Table 3b) 
Within the Black severe asthma group, allergic sensitization was still   associated with 
being in the high IgE group, but in contrast to the total population, this was not significant 
(p=0.3748). In contrast, having five or more positive  allergen skin  tests more than doubled the 
odds of being in the high IgE group (p=0.060). Having a skin reaction to D. pteronyssinus or 
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ragweed also was associated with a high IgE in the Black severe asthmatic group (p=0.013 and 
p=0.014, respectively). The size of the ragweed and tree wheals increased the odds of being in 
the high IgE group by 2% for every 1mm2 change (p=0.016 and p=0.05, respectively).  
Pet ownership did not significantly impact the likelihood of having a high IgE in the 
Black severe asthmatic group.  Neither obesity, diabetes, nor family histories of allergies or 
asthma were associated with IgE in severe asthmatics by univariable analysis.  
Systemic corticosteroid use was not a significant predictor of high IgE in Black severe 
asthmatics (p=0.1879). However, the odds of having a high IgE were reduced by almost 50% 
when a severe asthmatic was using systemic corticosteroids. 
Factors predicting severe asthma in those participants with High IgE (Table 4)  
In the univariable models for participants in the high IgE group, lower FEV1, FVC% 
predicted, FEV1 /FVC, and obesity were all strongly and positively associated with severe 
asthma.  Having diabetes, being unemployed, and having two or more family members with 
asthma were marginally associated with severe asthma. In contrast, 5 or more positive skin tests 
and many specific skin test reactions were negatively associated with severe asthma. Family 
history of allergies was not associated with severe asthma, while having several family members 
with a history of asthma greatly increased the odds of severe asthma (OR=2.75, p=0.06).  
4.3.3 Multivariate Models 
Factors predicting High IgE in All Asthmatic Population  
After adjusting for age, clinical center, and gender, the amount and type of allergic 
sensitization were associated with having high IgE in Black asthmatics, while the presence or 
absence of atopy was not. Five or more positive skin tests increased the odds of having a high 
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IgE by 1.5 but it was not a significant predictor. Sensitization to D. pteronyssinus doubled the 
odds of having high IgE group for all asthmatics. Having a furry pet other than a dog or cat 
significantly increased the odds of having a high IgE by 5 (p=0.044). 
Factors predicting High IgE in the Black Severe Asthma Population  
In Black severe asthmatics, the presence of a positive skin test reaction to D. 
pteronyssinus increased the odds of having a high IgE by four  (p=0.026), as compared to 2 in all 
asthmatics, The area of the ragweed allergen wheal also increased the odds of having a high IgE 
by 1% for every 1 mm2 change in wheal size (p=0.036). Unlike the results in all asthma, having 
multiple (????????????????????????????????????????????????????????? 
Factors predicting severe asthma in those participants with High IgE    
Participants in the high IgE group who had family members with asthma markedly 
increased the odds of having severe asthma, with the odds being  four times higher if a 
participant in the high IgE group had one family member with asthma (p=0.056), and almost six 
times higher for 2 or more family members (p=0.014). A Black asthmatic in the high IgE group 
who is obese had nearly triple the odds of having severe asthma (p=0.045). Having a positive 
skin reaction to D. pteronyssinus lowered the odds of having severe asthma by over 60% but this 
was not significant (p=0.163).  Interestingly, in the high IgE group, no lung function variable 
increased the risk for severe asthma. 
4.4 DISCUSSION 
In this study of Black asthmatics within the Severe Asthma Research Program, as expected, 
specific allergic sensitization is an important predictor of high IgE. In contrast, IgE itself, with 
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paradoxical protective effects of specific allergic sensitizations and positive contributions from 
genetics and obesity are the important predictors of severe asthma. While a stronger impact of 
total IgE to severe asthma than specific allergic skin reactions would not be surprising, the 
contradictory effects of the two clearly related factors remain difficult, but likely important, to 
understand.   
Black race has been shown to be associated with increased sensitization to indoor and 
outdoor allergens[5]. Having a positive skin reaction to certain allergens is strongly associated 
with being in the high IgE group. Increasing area of the skin test reaction to ragweed increased 
the odds of being in the high IgE group for all asthmatics and for severe asthmatics, supporting 
the concept that ragweed specific IgE levels are contributing directly to the measureable total 
IgE. In Black severe asthmatics, D. pteronyssinus reactions produced a four-fold increase in the 
likelihood of being in the high IgE group, while in all asthmatics the increase was two-fold. In a 
post hoc analysis, reactivity to D. pteronyssinus increased the odds of being in the high IgE 
group by three in Black mild/moderate asthmatics after adjusting for confounders, compared to 
four in the severe group (p=0.023). This suggests a stronger influence of dust mite sensitivity to 
IgE levels in Black asthmatics, and perhaps particularly in severe asthma.  
The protective effect D. pteronyssinus specific IgE to the development of severe asthma 
is particularly intriguing in Blacks with high IgE. On the one hand, high specific IgE to this dust 
mite allergen is associated with increased odds for high IgE in Black asthmatics, and severe 
asthmatics in particular. However, when predicting severe asthma in participants with high IgE, 
the D. pteronyssinus response is associated with decreased odds for severe asthma. The reasons 
for this paradox are not clear but may imply that although D. pteronyssinus specific IgE 
contributes greatly to the high total IgE, alternative (and not yet identified/measured in this 
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study) allergens contribute to the pathologic IgE. As all of our participants had asthma, we are 
unable to comment on the contribution of specific allergies or family history of allergies to 
asthma in general, rather only to severe asthma.  
We previously showed that family history of asthma was an important predictor of severe 
asthma for Blacks, a relationship confirmed in the current analysis[3]. The results indicate that 
within the high IgE group, the additional factor of a strong family history of asthma greatly 
increased the odds of having severe asthma, which is apparently independent of IgE or allergies. 
The relationship of family history (and personal history) of allergies to the development of 
asthma has long been controversial, with the strongest predictors for asthma generally accepted 
to be a family history of asthma, as opposed to allergies[17, 18]. However, our data do support a 
“dose response” for asthma related genetic factors in that increasing the number of family 
members with asthma greatly increases the odds of having severe asthma in Blacks with high 
IgE. 
This study clearly demonstrates an environmental contribution to high IgE levels. In all 
asthma, owning a furry pet other than a dog or a cat predicted having a high IgE level. Whether 
this is specific to a certain type of pet (i.e., rabbit) or is related to socioeconomic factors (more 
difficult to have a traditional pet in socioeconomically deprive households) remains to be 
addressed.  
Over 50% of Black asthmatics in this study met criteria for obesity.  Among Blacks in the 
high IgE group, obesity tripled the odds of having severe asthma compared to those who were 
not obese. The TENOR study of severe asthma also showed that Blacks were heavier and more 
likely to be severe[5]. A recent study of obesity in SARP began to tease out the relationship of 
obesity to severe asthma. In Black and White patients who developed asthma before the age of 
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12 (the majority of Black asthmatics), there was a linear relationship of increasing duration of 
disease with increasing obesity[19]. In this study, obesity (as opposed to duration of disease) was 
a predictive factor for severe asthma in Black asthmatics with high IgE levels. This would 
suggest that obesity per se, is more likely to be contributing to asthma severity as opposed to 
increasing duration of disease.    
Surprisingly, in Black asthmatics with high IgE, no pulmonary function test predicted 
severe asthma. FEV1 is generally one of the most robust predictors of severe asthma[20], such 
that the absence of these variables is particularly interesting. It suggests that IgE associated 
severe asthma in Blacks is more dependent on socioeconomic (obesity and employment) and 
immune factors (allergy) than lung function measures.   
The results of this study suggest that systemic corticosteroids block the increased 
production of IgE in Black severe asthmatics, as the univariate results indicate that the use of 
systemic corticosteroids is more prevalent in Black severe asthmatics with low IgE levels.  This 
would be consistent with systemic CS use decreasing allergic sensitization through effects on 
total IgE and the number of positive skin tests).  
This study is not without limitations. The size of the total Black population in this study 
was small but as the group was further stratified into a severe asthmatic group or high IgE group, 
the numbers became even smaller. Approximately 25% of the Blacks within the original SARP 
dataset were excluded because they did not have reported IgE levels. Some important categorical 
variables, such as atopy and inhaled corticosteroid use, due to collinearity within the severe and 
high IgE group. Therefore, comparisons were limited.  
In conclusion, our study suggests substantial differences in the factors that predict high 
IgE in all Black asthmatics compared to the severe asthmatics, with degree of allergic response 
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and environmental exposures more contributory in all asthmatics, and dust mite/ragweed reaction 
more specific to  severe asthmatics. It provides intriguing clues that, in fact, certain allergens and 
a family history of allergies, as opposed to asthma, may protect against severe asthma or high 
levels of IgE. This study again highlights the need for genetic studies conducted within the Black 
population to identify the genes that make Blacks susceptible to severe asthma, among other 
diseases. Finally, the impact of obesity and employment on the presence of severe asthma in 
Blacks with high IgE continue to underline an additional (and theoretically addressable) 
contribution of socioeconomic factors to severe asthma in Blacks, thus which should be carefully    
included in all genetic studies.     
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4.6 TABLES  
Table 7 Baseline Characteristics of Low and High IgE Groups in Black SARP Population 
Variable Low 
n=103 
High 
N=106 
Pvalue 
Female 80 (77.7%) 65 (61.3%) 0.0104 
Age of onset (yrs) 12 (4,26) 7 (2,18) 0.0174* 
Current Age (yrs) 36.6 (29.1,43.0) 32.6 (24.6,45.3) 0.1942 
Duration (yrs) 18.5 (10.6,29.8) 22.3 (14.4,29.7) 0.1192 
BMI 32.5 (27.4,38.6) 30.1 (25.0,36.5) 0.0582 
Currently employed 65 (63.1%) 65 (61.3%) 0.7901 
Presence of atopy 80 (77.7%) 94 (88.7%) 0.0164* 
???positive skin tests 29 (28.2%) 61 (59.2%) <0.0001
* 
Alternaria positive test 31 (30.1%) 42 (39.6%) 0.1942 
Grass Mix positive test 39 (37.9%) 70 (66.0%) <0.0001
* 
Cat positive test 31 (30.1%) 48 (45.3%) 0.0239* 
Dog positive test 17 (16.5%) 26 (24.5%) 0.1604 
Roach positive test 28 (27.2%) 48 (45.3%) 0.0053* 
Pteryn positive test 48 (46.6%) 74 (69.8%) 0.0007 
Tree positive test 24 (23.3%) 43 (40.6%) 0.0103 
Ragweed positive test 35 (34%) 63 (59.4%) 0.0002 
Alternaria, area 0 (0,30) 0 (0,49) 0.0598 
Grass Mix, area 0 (0,42) 49 (0,112) <0.0001
* 
Cat, area 0 (0,25) 8.5 (0,54) 0.0105* 
Dog, area 0 (0,0) 0 (0,20) 0.1041 
Roach, area 0 (0, 20) 9 (0,55) 0.0010* 
Pteryn, area 9 (0,42) 48.5 (0,99) 0.0004* 
Tree, area 0 (0,12) 0 (0,36) 0.0028 
Ragweed, area 0 (0,35) 37.5 (0,90) <0.0001
* 
Owns any pet 20 (19.4%) 31 (29.2%) 0.0899 
Owns a cat 6 (5.8%) 8 (7.5%) 0.5927 
Owns a dog 12 (11.7%) 18 (17.0%) 0.2474 
Owns an “other” pet 2 (1.9%) 10 (9.4%) 0.0173* 
Log Eosinophil -0.68 (-0.96,-0.51) -0.60 (-0.96,-0.39) 0.0023 
Diabetes 11 (10.7%) 4 (3.8%) 0.0505 
Obese 62 (60.2%) 54 (50.9%) 0.1785 
2ndhand smoke 33 (32.0%) 40 (37.7%) 0.3864 
1 family member with asthma 33 (32%) 40 (37.7%) 0.3585 
2+ family members with asthma 33 (32%) 31 (29.2%) 0.8741 
1 family member with allergies 39 (37.9%) 34 (32.1%) 0.1895 
2+ family members with allergies 44 (42.7%) 38 (35.8%) 0.1724 
FEV1, liters 2.23 (1.75,2.58) 2.18 (1.71,2.71) 0.9756 
FEV1 % predicted 77 (65,89) 75 (57,90) 0.2832 
FVC % predicted 86 (77,99) 91.1 (76,103) 0.2836 
FEV1/FVC 0.76 (0.67,0.81) 0.68 (0.59,0.76) 0.0003* 
Max FEV1 Reversal 11.7 (5.7,20.7) 17.7 (9.4,27.8) 0.0041* 
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Table 8 Baseline Characteristics of Low and High IgE Groups in Black Severe SARP Population 
Variable Severe N=76 Pvalue 
Low N=36 High N=40 
Female 27 (75.0%) 26 (65.0%) 0.3434 
Age of onset, yrs 13 (3.2, 28) 9 (1.5, 27) 0.4619 
Current Age, yrs 41.0 (35.1, 47.7) 41.5 (30.9,48.2) 0.9875 
Duration, yrs 25.0 (11.9,34.7) 23.8 (15.3,36.3) 0.6584 
BMI 33.0 (29.3,41.6) 32.8 (26.9,36.7) 0.2816 
Currently employed 22 (61.1%) 21 (52.5%) 0.4495 
Presence of atopy 25 (69.4%) 31 (77.5%) 0.4965 
≥5 positive skin tests 8 (22.2%) 17 (42.5%) 0.0571 
Alternaria positive test 9 (25.0%) 12 (30.0%) 0.6474 
Grass Mix positive test 13 (36.1%) 22 (55.0%) 0.0892 
Dog positive test 7 (19.4%) 10 (25.0%) 0.5314 
Roach positive test 8 (22.2%) 16 (40.0%) 0.0762 
Pteryn positive test 9 (25%) 21 (52.5%) 0.0110 
Tree positive test 9 (25%) 15 (37.5%) 0.2439 
Ragweed positive test 7 (19.4%) 18 (45%) 0.0114 
Alternaria, area 0 (0,24) 0 (0,32.5) 0.8421 
Grass Mix, area 0 (0,39) 28 (0,80) 0.0820 
Cat, area 0 (0,41.5) 0 (0,51) 0.4755 
Dog, area 0 (0,75) 0 (0,4.5) 0.7727 
Roach, area 0 (0,7.5) 0 (0,52.5) 0.1827 
Pteryn, area 0 (0,7.5) 20 (0,71) 0.0277* 
Tree, area 0 (0,10) 0 (0,47) 0.3926 
Ragweed, area 0 (0,45) 0 (0,84) 0.0101 
Owns any pet 6 (16.7%) 12 (30.0%) 0.1725 
Owns a cat 2 (5.6%) 1 (2.5%) 0.5999 
Owns a dog 4 (11.1%) 8 (20.0%) 0.2898 
Owns an “other” pet 1 (2.8%) 3 (7.5%) 0.6145 
Log Eosinophil -0.82 (-0.96,-0.68) -0.54 (-0.96,-0.44) 0.0450* 
Diabetes 4 (11.1%) 3 (7.5%) 0.7041 
Obese 26 (72.2%) 27 (67.5%) 0.6546 
2ndhand smoke 9 (25.0%) 16 (40.0%) 0.2220 
Systemic Corticosteroid use 18 (50%) 14 (35%) 0.1860 
1 family member with asthma 11 (30.6%) 14 (35.0%) 0.3017 
2+ family members with asthma 11 (30.6%) 16 (40.0%) 0.2012 
1 family member with allergies 12 (33.3%) 10 (25.0%) 0.4434 
2+ family members with allergies 13 (36.1%) 16 (40.0%) 0.8898 
FEV1, liters 1.75 (1.43,2.23) 1.74 (1.35,2.18) 0.6967 
FEV1 % pred 69.5 (58.5,80.5) 62 (47.5,80.5) 0.5121 
FVC % pred 78 (72.6,97) 83.4 (68,95) 0.7279 
FEV1/FVC 0.71 (0.61,0.79) 0.63 (0.53,0.72) 0.0880 
Max FEV1 Reversal 12.4 (6.2,18.1) 17.7 (9.4,31.5) 0.0719 
 84 
 
Table 9 Univariable Models for Black SARP Participants: Predicting the Odds of Having High IgE 
Variable OR 95% CI Pvalue 
Age of onset 0.977 0.956-0.998 0.0294 
Currently Employed 0.927 0.530-1.622 0.7901 
Presence of Atopy 3.819 1.198-12.177 0.0235 
≥5 positive skin tests 3.638 1.998-6.624 <0.0001 
Alternaria positive test 1.478 0.819-2.669 0.1951 
Grass Mix positive test 3.461 1.897-6.316 <0.0001 
Roach positive test 2.321 1.278-4.217 0.0057 
Dog positive test 1.637 0.820-3.269 0.1625 
Cat positive test 1.347 0.450-4.031 0.5939 
Pteryn positive test 2.882 1.546-5.374 0.0009 
Tree positive test 2.215 1.200-4.089 0.0110 
Ragweed positive test 3.109 1.714-5.639 0.0002 
Alternaria, area 1.006 0.999-1.013 0.0893 
Grass Mix, area 1.005 1.001-1.009 0.0094 
Cat, area 1.005 1.000-1.011 0.0734 
Dog, area 1.011 0.998-1.025 0.1070 
Roach, area 1.008 1.001-1.016 0.0311 
Pteryn, area 1.006 1.002-1.010 0.0050 
Tree, area 1.015 1.005-1.026 0.0044 
Ragweed, area 1.012 1.006-1.018 0.0001 
Own any pets 1.741 0.914-3.317 0.0918 
Own cat 1.347 0.450-4.031 0.5939 
Own dog 1.588 0.722-3.494 0.2500 
Own “other” pet 5.439 1.161-25.485 0.0316 
Log Eosinophil 1.340 0.750-2.395 0.3235 
Diabetes 0.324 0.100-1.054 0.0610 
Obese 0.687 0.397-1.188 0.1792 
2ndhand smoke 1.289 0.725-2.291 0.3868 
1 Family member with asthma 1.364 0.703-2.646 0.3590 
2+ family members with asthma 1.057 0.534-2.093 0.8741 
1 Family member with allergies 0.604 0.283-1.286 0.1909 
2+ family members with allergies 0.598 0.285-1.255 0.1739 
FEV1 % predicted 0.994 0.981-1.007 0.3728 
FVC % predicted 1.009 0.993-1.025 0.2752 
FEV1, liters 1.015 0.693-1.486 0.9396 
FEV1/FVC 0.026 0.002-0.296 0.0032 
Max FEV1 Reversal 1.025 1.007-1.044 0.0074 
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Table 10 Univariable Models for Black SARP Participants in the Severe Phenotype Group: 
Predicting the Odds of Having High IgE 
Variable OR 95% CI Pvalue 
Age of onset 0.989 0.960-1.020 0.4905 
Currently Employed 0.703 0.282-1.753 0.4501 
Presence of Atopy 1.860 0.472-7.323 0.3748 
?????????????????????? 2.715 0.957-7.699 0.0604 
Alternaria positive test 1.275 0.449-3.620 0.6477 
Grass Mix positive test 2.343 0.871-6.303 0.0917 
Roach positive test 2.555 0.895-7.296 0.0797 
Dog positive test 1.429 0.466-4.376 0.5323 
Cat positive test 0.434 0.038-5.009 0.5038 
Pteryn positive test 3.769 1.328-10.698 0.0127 
Tree positive test 1.833 0.658-5.107 0.2462 
Ragweed positive test 3.943 1.327-11.712 0.0135 
Alternaria, area 1.002 0.991-1.014 0.6910 
Grass Mix, area 1.005 0.998-1.011 0.1741 
Cat, area 1.000 0.990-1.011 0.9346 
Dog, area 0.995 0.971-1.019 0.6660 
Roach, area 1.002 0.994-1.009 0.7040 
Pteryn, area 1.007 0.998-1.016 0.1480 
Tree, area 1.017 1.000-1.035 0.0503 
Ragweed, area 1.015 1.003-1.027 0.0155 
Own any pets 2.148 0.707-6.526 0.1776 
Own cat 0.434 0.038-5.009 0.5038 
Own dog 2.000 0.545-7.333 0.2958 
Own “other” pet 3.000 0.297-30.345 0.3521 
Log Eosinophil 1.548 0.655-3.659 0.3193 
Diabetes 0.667 0.139-3.207 0.6129 
Obese 0.799 0.298-2.138 0.6548 
2ndhand smoke 1.855 0.684-5.027 0.2245 
1 Family member with asthma 1.838 0.576-5.865 0.3036 
2+ family members with asthma 2.101 0.668-6.604 0.2039 
1 Family member with allergies 0.625 0.187-2.085 0.4445 
2+ family members with allergies 0.923 0.297-2.865 0.8898 
Systemic corticosteroid use 0.538 0.214-1.353 0.1879 
FEV1 % predicted 0.997 0.976-1.018 0.7653 
FVC % predicted 1.003 0.976-1.030 0.8438 
FEV1, liters 1.008 0.470-2.162 0.9841 
FEV1/FVC 0.079 0.002-2.998 0.1711 
Max FEV1 reversal 1.039 1.002-1.076 0.0366 
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Table 11 Univariable Models for Black SARP Participants in the High IgE Group: Predicting the 
Odds of Having Severe Asthma 
Variable OR 95% CI P-value 
Age of onset 1.021 0.99-1.052 0.183 
Employed 0.553 0.247-1.235 0.148 
?????????????????????? 0.408 0.174-0.958 0.040 
Alternaria positive test 0.557 0.236-1.312 0.181 
Grass Mix positive test 0.529 0.215-1.298 0.164 
Roach positive test 0.833 0.361-1.926 0.670 
Dog positive test 1.224 0.483-3.104 0.670 
Cat positive test 1.032 0.448-2.377 0.941 
Pteryn positive test 0.305 0.116-0.802 0.016 
Tree positive test 0.938 0.407-2.158 0.879 
Ragweed positive test 0.480 0.200-1.153 0.101 
Alternaria, area 0.994 0.984-1.004 0.248 
Grass Mix, area 0.997 0.992-1.002 0.230 
Cat, area 0.995 0.987-1.003 0.198 
Dog, area 0.981 0.960-1.003 0.090 
Roach, area 0.998 0.989-1.007 0.706 
Pteryn, area 0.992 0.986-0.999 0.024 
Tree, area 1.001 0.991-1.010 0.860 
Ragweed, area 0.999 0.994-1.003 0.499 
Own any pets 1.076 0.453-2.555 0.868 
Own cat 0.214 0.025-1.813 0.157 
Own dog 1.394 0.498-3.901 0.527 
Own “other” pet 0.753 0.182-3.111 0.695 
Log Eosinophil 0.837 0.406-1.724 0.6288 
Diabetes 5.417 0.543-54.0 0.149 
Obese 3.000 1.316-6.837 0.009 
2ndhand smoke 1.159 0.514-2.618 0.722 
1 Family member with asthma 1.376 0.502-3.770 0.535 
2+ family members with asthma 2.725 0.959-7.742 0.060 
1 Family member with allergies 0.486 0.167-1.413 0.185 
2+ family members with allergies 0.848 0.311-2.317 0.749 
Systemic corticosteroid use 6.461 2.108-19.803 0.001 
FEV1 % predicted 0.972 0.952-0.992 0.0056 
FVC % predicted 0.970 0.948-0.992 0.008 
FEV1, liters 0.233 0.111-0.489 0.0001 
FEV1/FVC 0.010 <0.001-0.411 0.015 
Max FEV1 Reversal 1.004 0.986-1.023 0.672 
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Table 12 Multivariate Model for Black SARP Participants: Predicting the Odds of Having High IgE 
Variable OR 95% CI Pvalue 
Age of onset 0.985 0.958-1.01 0.295 
Have “other” pet 5.263 1.049-26.414 0.044 
?????????????????? 1.584 0.732-3.425 0.243 
Pteryn positive test 2.191 1.037-4.628 0.040 
Ragweed, area 1.008 1.001-1.015 0.011 
 
Table 13 Multivariate Model for Black SARP Participants in the Severe Phenotype Group: 
Predicting the Odds of Having High IgE 
Variable OR 95% CI Pvalue 
Ragweed, area 1.014 1.001-1.028 0.036 
Pteryn positive test 3.896 1.174-12.930 0.026 
 
Table 14 Multivariate Model for Black SARP Participants in the High IgE Group: Predicting the 
Odds of Having Severe Asthma 
Variable OR 95% CI Pvalu
e 
Obesity 2.784 1.021-7.589 0.045 
Employed 0.393 0.141-1.096 0.074 
Pteryn positive test 0.429 0.131-1.409 0.163 
1 family member with asthma 3.850 0.965-15.354 0.056 
2+ family members with asthma 5.704 1.425-22.841 0.014 
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5.0  POLICY RECOMMENDATIONS FOR REDUCING THE DISPARITY 
BETWEEN BLACK AND WHITE SEVERE ASTHMATICS 
5.1 INTRODUCTION 
Asthma is a complex respiratory disease that has been increasing in prevalence in the United 
States since 1980 despite advances in treatment. It is estimated that 32.6 million people (1 in 10 
Americans) in the United States has had asthma at one point in their lives; while 22.2 million 
people (1 in 14 Americans) are currently diagnosed with asthma[1]. Among the over 20 million 
people with asthma, over 12 million have had an asthma attack within the past 12 months[1]. 
Asthma is associated with high morbidity and mortality. In the United States, about 30,000 
people a day have an asthma attack, while 5,000 people have an emergency department visit and 
1,000 people are admitted to the hospital due to their asthma[1]. Almost 11 Americans die each 
day due to their asthma, while 4,000 die annually from complications related to asthma[1].  Due 
to these statistics, asthma has become an increasing burden on the individual diagnosed with 
asthma and the American health care system, costing $19.7 billion annually[1].  
5.1.1 Severe Asthma 
Although there are treatments that can control asthma, there are still a small number of 
asthmatics (about 10%) that are not able to control their asthma despite the use of the highest 
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treatment level (i.e., high dose of inhaled corticosteroids (ICS))[2-4]. Individuals with severe 
asthma are characterized by their inability to have their asthma controlled with current available 
medications. They have persistent daily symptoms, daily bronchodilator use, asthma-related 
nocturnal symptoms at least once a week, and a force expiratory volume in 1 second of less than 
75% predicted for their age, height, sex, and race[3].   
Having lower lung function, a history of pneumonia, less atopy, and being Black has 
been shown to be associated with having more severe and frequent exacerbations, hence 
suggesting their contribution to the development of severe asthma[5,6]. Currently, there is no 
way to determine if a patient with asthma is at risk of developing severe asthma.  
5.1.2 Economic Burden 
Due to asthma being a chronic condition, use of daily medication is needed to control the 
disease; however, despite effective prophylactic therapy available to asthmatics, the prevalence 
and severity are steadily increasing. Asthmatics not properly managing their asthma by under-
using medications have resulted in the health systems incurring substantial costs[7]. In addition, 
severe asthma continues to excessively contribute to the economic burden and costs of asthma 
due to the difficult nature of the disease[8]. In 2005, 1% of the total health care cost for the 
United States was attributed to asthma costs. Treating uncontrolled and severe asthma accounted 
for the majority of these costs[7].  
Individuals with asthma tend to acquire a considerable financial burden because of their 
asthma[9]. Direct, indirect, and intangible costs to asthma care can negatively affect the 
individual with asthma and their family. Direct costs consist of costs associated with physician 
costs, hospital costs, and drug costs. Physician costs account for the smallest amount of asthma 
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costs. Typically, 20-25% of the direct costs for asthma are for hospital care such as in-patient 
care or emergency room care. Patients with more severe asthma tend to incur these hospital 
costs. Drug costs are the most expensive component of direct costs for asthma making up 37% of 
the total asthma direct cost. Poor compliance with asthma medication results in an increase in 
asthma morbidity, thus, resulting in an increase in the costs associated with asthma[7]. 
Indirect costs consist of resources that are lost due to the disease such as premature 
retirement, time off of work, absenteeism, or death. These costs occur only when asthma has 
become intrusive into the lifestyle of the individual. These costs vary depending on the severity 
of the asthma and age of the individual[7]. Hospitalizations and urgent care have resulted in 
almost $20 billion in annual asthma health care costs, direct and indirect included[1]. 
Absenteeism is a common problem associated with asthma morbidity. Every year, over three 
million days of work and ten million days of school are lost due to asthma[10].  
Intangible costs occur when the quality of the individual’s life is impaired. These costs 
also vary depending on the age of the individual and severity of the asthma[7]. Individuals with 
asthma may become depressed or feel as though their lives are very restricted or limited due to 
their asthma, thereby, resulting in a decrease in their quality of life. The more severe the asthma, 
the higher the costs associated with asthma care[7]. 
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5.2 BACKGROUND 
5.2.1 Racial Disparities 
In 2002, it was reported by the Centers for Disease Control and Prevention (CDC) that the 
prevalence of asthma in Blacks was approximately 38% higher than Whites. The CDC also 
reported that the asthma morbidity was drastically higher in Blacks than Whites. Compared to 
Whites, Blacks had 225% higher hospitalization rates, a 200% higher asthma death rate, 30% 
higher frequency of asthma attacks, and a 380% higher rate of visits to the emergency room[11]. 
In 2008, the American Lung Association reported that 105.5 per 1000 Blacks had asthma 
compared to 782 per 1000 Whites[12] The cause for this disparity in asthma between Blacks and 
Whites is unknown, however, several studies have suggested a possible biological or genetic 
reason for the increased prevalence and severity of asthma in the Black population. The 
Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) 
study investigated the differences in asthma severity between Blacks and Whites[13]. In their 
study, they were able to show that Blacks were more likely to have severe asthma and use three 
or more long-term controllers. Black participants were also more likely to report not using their 
medication or taking medication on some days but not on all days resulting in Blacks having 
more asthma control problems. 
Past studies have shown that Blacks with asthma report their asthma symptoms 
differently than their White counterparts. Blacks primarily report upper respiratory symptoms; 
whereas, Whites report lower airway symptoms which is associated with asthma-related 
symptoms[14]. This is likely to lead to asthma in blacks being undiagnosed. 
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5.2.2 Genetics 
The etiology of asthma is unknown; however, studies have shown that asthma cannot be fully 
explained by environmental, social, cultural, or economic factors. With the availability of genetic 
mapping and the increasing popularity of genetic epidemiology in the past two decades, genetics 
has been shown to play a role in the development of asthma[15, 9, 16]. 
Unfortunately, there were a limited number of studies that have looked at the genetic link 
to asthma; therefore, it is unknown how much genetic susceptibility contributes to the 
development of asthma and the disparities in asthma[15]. The limited studies have, however, 
shown that individuals of African descent have more severe asthma than those of European 
descent[15]. It is difficult to completely understand the role that genetics plays in the 
development of asthma for Blacks due to most of the genetic studies being underpowered and the 
variety of environmental factors that are unique to Blacks[16]. These environmental factors 
further support the theory of there being a gene-by-environment interaction associated with 
asthma, especially in Blacks[14].  
5.2.3 Allergic sensitization 
Allergies have been shown to play a major role in the development of asthma. Asthma has been 
often described as an atopic disease, with atopy being defined as skin prick test (SPT) positivity 
or the development of IgE in response to environmental allergens. Pearce et al describes the 
paradigm between asthma and allergies as the exposure to allergen causing sensitization and 
continued exposure leading to clinical asthma[17]. A meta-analysis carried out by Pearce et al 
showed that on average there were approximately 37% of asthma cases that were attributable to 
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atopy in adults[17]. Although atopy and asthma have been frequently studied, the relationship 
and its influence on asthma severity are complex and not well understood.  
Exposure to allergens is known to be associated with increased airway 
hyperresponsiveness, asthma symptoms, and severe asthma. Cockroaches and dust mites are 
examples of indoor exposures that have been shown to be associated with asthma severity[18]. 
Dust mites have been shown to trigger asthma attacks and increase asthma symptoms, more so 
among those living in  the inner city. Positive allergen skin tests to cockroaches have also been 
linked to asthma severity with a higher incidence of positive skin tests in Blacks[18, 14]. Togias 
et al suggested that there may be genetic factors that are involved with the higher sensitivity to 
cockroaches in the Black population, mainly Black population in inner cities; hence, signifying a 
strong association to environmental exposures for Blacks[19]. 
5.3 PRE-EXISTING POLICY 
There is currently no existing legislation regarding severe asthma nor asthma in adults. Most 
pending legislation or policy regards the management of asthma within children in schools. It 
can be inferred that legislation or policies concerning the management of asthma in adults would 
not be effective because of the difficulty in changing the attitudes and behaviors of adults. 
However, there has been legislation related to risk factors for developing severe asthma, such as 
smoking. The introduction of smoking bans have decreased the amount of secondhand smoke 
that asthmatics have to encounter during their daily lives[20]. The smoking legislation prohibits 
smoking in public places, as well as in the workplace. 
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5.4 RECOMMENDATIONS 
Reducing racial disparities in severe asthma, and asthma in general, has been difficult to 
accomplish. The gap between White and Black asthmatics still exists; therefore, I present five 
recommendations that would lead to closing the gap between the races. The recommendations 
focus on both the asthmatic and the health care system. 
1. Improve and increase asthma education among Black asthmatics. 
Asthma has become a disease that is common and underestimated; hence, lowering the 
importance of being educated about the disease and its possible deadly effects. Asthmatics must 
be educated about the disease process to completely understand the disease that they are dealing 
with and how to effectively manage the disease. Asthmatics must be taught how to correctly use 
their inhalers and what are the appropriate emergency procedures that must occur in the instance 
of an exacerbation. Asthmatics, mainly severe asthmatics, must have access to a primary care 
physician who is familiar with their medical history and can monitor their disease and make 
changes as deemed necessary. Also, asthmatics must be made aware of the allergens that have 
the potential to cause exacerbations or worsen their asthma. Because it is unclear as to how 
severe asthma develops or if individuals with mild or moderate asthma will develop severe 
asthma, asthmatics must be educated on the risk factors associated with severe asthma.  
Community education fairs, hospital educational sessions, or trained community 
advocates can be utilized to help disseminate the information that will educate asthmatics about 
their asthma. This information is very important to severe asthmatics and should be provided at 
each visit to a medical facility, including the emergency department. 
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2. Improve asthma management for Black asthmatics.  
According to the American Lung Association, “adequate healthcare is integral to 
reducing the burden of asthma”[12]. Black asthmatics, including severe asthmatics, must have 
access to proper preventive care and treatment, so that they can no longer use the emergency 
department as their primary care when an asthmatic episode occurs[12]. Management of asthma 
is essential to reducing the prevalence of asthma in Blacks. Research has shown that children 
with a management plan are less likely to have asthma symptoms; however, Black children were 
less likely to have a management plan compared to their White counterparts[12]. There is a need 
for this population to improve adherence and compliance when it comes to their asthma, such as 
adhering to scheduled appointments or prescribed medical regimens. The Halm study revealed 
that low-income, inner-city patients believed that they only had asthma when they were 
symptomatic, which was associated with lower inhaled corticosteroid use (ICS)[21].  Similarly, 
the Lee study showed that Black adults were less likely to use their ICS inhaler compared to 
White adults due to the negative beliefs associated with ICS therapy in Black patients[22]. Black 
patients felt that there was less of a need to use a controller for their asthma if their asthma 
symptoms did not occur frequently or daily. This contributes to poor asthma control, which in 
turn leads to the delay in diagnosing severe asthma and the increased use of emergency 
department care due to the prolonged treatment of asthma[23]. 
Studies have shown that allergy testing is not a routine component of treatment for 
asthma; therefore, individuals do not have specific documentation as to their allergic status that 
may motivate them to take positive steps to improving or managing their health[24]. The 
TENOR study revealed that there needs to be more of an emphasis on allergy testing within the 
Black population to better manage the asthma in this population[13].  
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Lung function is correlated to asthma severity. Asthma severity can be measured 
according to the potential for frequent exacerbations and the degree of airway obstruction 
(disease severity) measured as baseline forced expiratory volume in one second (FEV1)[13]. In 
Gamble et al, pulmonary function was highly associated with severe asthma [25]. This fact 
illustrates the need for mandatory spirometry testing for every patient who displays the 
symptoms of asthma and those who have been diagnosed previously with asthma. 
Health care providers must be trained and educated on the racial differences in asthma to 
effectively treat the disease in the Black population. Blacks have been shown to describe their 
asthma problems differently than their White counterparts[14]; therefore, providers must be 
proactive in testing Black patients who present any breathing problems for asthma. Providers 
must also be aware of the National Asthma Education Prevention Program (NAEPP) guidelines 
and adhere to them. Referrals of Black asthmatics to pulmonologists and allergists by primary 
care providers must be routinely done to ensure the patient is getting the appropriate care to 
manage their asthma. 
3. Utilize racial and ethnic disparities in severe asthma to develop appropriate health care 
interventions. 
Access to quality medical care is correlated with access to health insurance. While the 
number of Black asthmatic children having access to health care has increased due to the 
creation of the State Children’s health Insurance Program, the number of Black adult asthmatics 
having access to health care has steadily decreased[26]. This issue has contributed to the racial 
disparity seen in asthma.  
A report by the Institute of Medicine revealed that there are systemic health care factors, 
such as stereotyping, bias, and clinical uncertainty, which contribute to the racial disparity in 
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asthma[23]. The Okelo study showed that physicians often underestimate asthma severity in 
minority patients. Studies have shown that Black asthmatic children received fewer controller 
and reliever medications compared to White asthmatic children[27]. Also, Black adults reported 
having fewer medication recommendations from providers than White adults. In regards to 
asthma management, fewer Black adult asthmatics reported receiving education on self-
management of asthma. Providers must adhere to NAEPP guidelines, which lead to a reduction 
in health care utilization (emergency department visits, hospitalizations, etc) by asthmatics. Also, 
communication between physicians and Black asthmatic patients is critical to improving asthma 
care in Blacks and reducing the racial disparity[27]. 
Increasing the number of physicians working in low-income areas will help to reduce the 
racial disparity seen in asthma and severe asthma. Medical students, medical residents, and 
physicians should be given incentives to work in neighborhoods that do not provide access to 
quality health care. Underdiagnosis of asthma contributes to the racial disparity; hence, the 
increased access to medical care can aid in reducing the disparity. 
Due to the differences in the genetics of Black and White asthmatics, there is a need to 
differentiate between the medications used to treat asthma in the two populations. The TENOR 
study has suggested that there be customized treatment regimens and education strategies 
specifically for Black asthmatics[13]. This is preferred due to recent study results showing the 
increase in mortality of Blacks using LABA[13]. 
4. Conduct more research studies, mainly genetic studies, with Black participants.  
Studies have shown that there may be an environment-genetic interaction occurring in the 
development and severity of asthma. To effectively study the disease in Blacks, researchers must 
be cognizant of the fact that Blacks tend to be exposed to different environmental factors 
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compared to their White counterparts. Black race is associated with more exposure to indoor and 
outdoor pollution such as secondhand smoke, diesel emissions, and lead. Also, studies have 
shown that Blacks may have genes that make them susceptible to more severe asthma[13, 16]. 
The American Lung Association has suggested that due to the complexity of asthma and the 
varying levels of genetic and environmental factors that are influential in the asthma process, 
researchers must conduct large studies on Black populations[12]. In order to properly treat and 
manage severe asthma in Blacks, there needs to be an increase in the amount of studies 
conducted with Black participants. Most studies either do not have Black participants or there is 
a dismal amount of Black participants, which result in a very low, if any, external validity[12, 
16]. Relatively few genetic studies have included Blacks, as well as other minorities. This is 
disappointing given the “potential impact of genetic studies on reducing disparities in the 
prevention and treatment of asthma”[16]. There is also a need to not only have more asthmatic 
Black participants but also more Black healthy controls to determine the true effect of the 
environment and genetics on the Black asthmatic population.  
One possible solution to this problem is for researchers to make a presence in Black 
communities and to use these resources to recruit healthy and asthmatic Blacks. Due to the Black 
community having distrust with the medical system, this is an important step to ensure that 
asthma is Blacks is well studied and, eventually, managed. Properly training investigators and 
using investigators who are highly motivated to study asthma in the Black population can 
overcome the issue of low recruitment of Blacks. 
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5. Introduce more legislation regarding risk factors for asthma and severe asthma in 
adults. 
Due to the growing number of lawyers being trained in public health law, there has been 
an increase in the introduction of more regulations or legislation focused on improving the 
public’s health. The smoking ban is one success in the field of public health law that has aided in 
reducing the detrimental effects of air pollution on asthmatics; however, there is a need for more 
legislation or policies regarding risk factors associated with severe asthma. Possible legislation 
can focus on the reduction of diesel emission in urban neighborhoods, the increase of city parks 
that are conducive for physical activity, creation of funds for low-income or uninsured 
individuals with chronic diseases to help pay for preventive and disease management services, 
and mandatory allergy testing for every asthmatic treated at a medical facility. The American 
Lung Association continues to publish the “State of Lung Disease in Diverse Communities” but 
it is not published every year, unlike their numerous tobacco reports. This report should be used 
by local, state, and federal governments to ascertain future directions for legislation, policies, and 
regulations to eliminate asthma, as well as other lung diseases. Robert Wood Johnson 
Foundation’s Allies Against Asthma coalition was created primarily to reduce the racial and 
economic disparities within childhood asthma through the use of policy to change the current 
state of asthma[28]. Creating a similar coalition focused on adult asthmatics, mainly severe 
asthmatics, would aid in creating effective legislation to reduce the racial disparities in adult 
asthma. 
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5.5 CONCLUSION 
In conclusion, these recommendations will have a tremendous effect upon the life of the 
asthmatics and the health care system. The cost of health care is very high for asthmatics and 
even higher for severe asthmatics [7]. Education, asthma management plans, research studies 
with large Black populations, and asthma regulations will decrease the costs of health care for 
the asthmatic and health care system dramatically if they are followed; therefore, it is imperative 
that these recommendations be implemented to reduce the racial disparity seen in asthma and 
severe asthma. 
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6.0  DISSERTATION WORK LIMITATIONS 
The cross-sectional study design is a limitation of this study. It is difficult to confirm a temporal 
relationship in regards to severity and the variables of interest. Did the severity result in high 
BMI, low quality of life, or breathing problems or is this relationship the reverse? Were some 
individuals categorized as mild or moderate before they became severe or did they always have 
severe asthma? Another concern is the lack of incident data that could strengthen the data. Only 
prevalent cases can be studied in this project. There are many questions that cannot be answered 
due to the disadvantages of this study design.  
Another limitation is the lack of data on the subject’s type of health care insurance, 
marital status, education, and income. The first aim of this study focuses on health care 
utilization. The disparity that may be seen once this aim is analyzed may be explained more if an 
insurance variable were added. Including an insurance variable could have strengthened the 
analysis for this aim. To effectively look at the racial disparity in health care utilization, it is 
important to see the role of insurance in this relationship. Also, demographic and socioeconomic 
variables such as education and income have been shown to influence the relationship between 
race and asthma severity. This study was not able to analyze the impact of these variables on that 
relationship. Marital status would have been an interesting variable to analyze since there are no 
known studies that have looked at this variable in relation to asthma severity in Blacks and 
Whites.  It is better to have a complete “picture” of the disparity among individuals in the severe 
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phenotype group and these variables would have provided more information on the disparity in 
severe asthma. 
Lack of power may be an additional limitation in this project for the last specific aim, 
comparing mild/moderate and severe asthma groups among Blacks in SARP.  This analysis 
would be important to look at to determine if there is more to the disparity between the two 
severe groups (Blacks and Whites) than race. There could be additional factors that add to the 
disparity seen in asthma and severe asthma for Blacks. There is the possibility that another 
variable within the dataset explains some of the disparity seen in many studies and possibly this 
study. 
The number of Black participants was significantly smaller than the White participants. 
In paper two, the small number of Black participants got smaller when breaking the group down 
into Black severe asthmatics and Black asthmatics with high IgE. 
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7.0  FUTURE RESEARCH DIRECTIONS 
This research has led to the suggestion of several possible studies and analyses in the future. 
First, due to the low number of Black participants in genetic studies and the clear disparity 
between Black and White severe asthmatics, a genetic epidemiology study must be conducted 
with Black participants. Second, an analysis should be carried out to look at the influence of 
socioeconomic variables on asthma severity in Black and White asthmatics. Third, pet ownership 
was shown to be a predictor of high IgE in Blacks. This association should be looked into further 
to determine the true effects of the variable. Fourth, a seasonal allergen study should be 
conducted. Blacks have been shown to be highly sensitized to indoor and outdoor allergens. 
Looking at the month of birth and allergens to determine if there is a certain time of year when 
severe asthmatics were born is another suggested future study. Lastly, Blacks have more severe 
asthma, more health care utilization due to their asthma, and disparate treatment of their asthma 
compared to Whites. Quality of life are affected by these variables and more so it would be 
important to look at the effect of severe asthma on a Black asthmatics life compared to their 
White counterpart. The SARP study is steadily increasing their Black population to carry out 
some of these suggested studies. 
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8.0  PUBLIC HEALTH SIGNIFICANCE 
Asthma has a financial and emotional burden on asthmatics and their families, especially if they 
have the severe form of this disease. If severe asthma is controlled, the financial burden to the 
individual and family will be reduced; therefore, increasing their income[18]. Asthma control is 
imperative to the management of asthma, especially in Blacks and low-income individuals. 
There are several public health implications that can arise out of this project and future projects 
based on these analyses. The results of this project show a racial difference in asthma 
pathophysiology, which can result in the need for different treatment and management of asthma 
in Blacks and Whites. Compared to their White counterparts, Blacks may be predisposed to more 
severe asthma and frequent asthma exacerbations. Due to the link between atopy and asthma, it 
is important to ensure that asthmatics are tested for allergies; however, the relationship between 
positive SPTs and severe asthma is not conclusive.  This study could raise the possibility that 
there is an association between the two, mainly in Blacks. The role that eosinophils play in 
asthma pathogenesis has been a topic of debate. This study may provide more information about 
eosinophils, SPTs, and asthma severity. Past studies have, also, shown that Blacks have a smaller 
lung capacity than Whites. This result, combined with others, led to the introduction of a race 
corrected FEV1. The results from this study can also have a similar impact on clinical care. 
GINA guidelines and pocket references have been updated and in use around the world; 
however, the control and management of asthma has continued to be a challenge for asthma care, 
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mainly for Blacks and other minorities. The results from this study can help to inform and 
reiterate the need for the training of clinicians in the area of physician-patient communication 
and cultural/racial beliefs. Clinicians need to actively listen and communicate with patients, 
especially Black patients, to ensure that they are educated about their asthma (health literacy), 
diagnosed earlier to avoid severity, and receiving quality and equitable care. The management of 
asthma can lead to the improvement of the quality of life of patients, decrease absenteeism at 
work or school, and decrease the prevalence of severe exacerbations. A decrease in the amount 
of dollars used to pay for the excess of medical resources that are used by asthmatics is also 
another result of effectively managing asthma. This project will add to the current knowledge 
about the racial differences in asthma severity. 
 This study also highlights the need for the important role that IgE plays in Black 
asthmatics and the needs for genetic studies to further understand its role in the development of 
severe asthma in Blacks. The role of sensitization to specific allergens such as dust mite and 
cockroach in Blacks was highlighted in this study. Also, this study eludes to the fact that there 
could be possible ways to identifying severe asthma in Blacks and Whites, which could aid in the 
early detection and treatment of problems associated with asthma severity. Genetics, mainly 
family history of asthma, and allergic sensitization were shown to be predictors of severe asthma 
in Blacks; while comorbidities, such as diabetes and hypertension, were predictors of severe 
asthma in Whites. 
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